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ABSTRACT
Utilizing early cellular changes to explore biological responses to individual chemical
and mixture exposures
by
Julie Anne Vrana
Humans are continuously exposed to a vast number of chemicals, whether it be
from the air we breathe, the water we drink, or the medications we take daily. Early
cellular changes after exposure to chemical insult, both individual chemicals and
mixtures (two or more chemicals) thereof, can offer a wealth of information about
cellular adaptation (e.g., cell death or survival decision processes). From this
understanding, better prediction models for chemical risk assessment, such as toxicity or
carcinogenicity, can be elucidated. Further, these prediction models can greatly improve
the large backlog of chemicals waiting to be evaluated for potential adverse effects. One
approach to understand cellular changes and responses after chemical or mixture
exposure is with toxicodynamics. From a toxicodynamic approach, a host of information
can be determined, such as spatiotemporal interactions of chemical insult with biological
targets, the corresponding disruption of intracellular pathways and bioenergetics, and
downstream effects after exposure. Appropriately measuring these dynamic cellular
changes is imperative. The recent advances in molecular biology, high-throughput in
vitro screening assays, and numerous computational techniques have allowed
toxicologists to collect large data sets on signaling pathways that are perturbed in
response to chemical insults. From these early cellular perturbations, whether they be
signaling proteins, biomolecules (e.g., ATP, hormones, NADH), or ions (e.g., Ca2+ or
K+), in response to a wide range of doses, especially low concentrations, improved risk
assessment prediction models for individual chemical and mixture exposures can be
utilized by many fields, such as risk assessment for environmental toxicology and target
molecule/pathway analysis for drug development and pharmacology.
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Chapter 1
Introduction to early cellular changes that may contribute to
individual and mixture responses after exposure

2
1. Introduction: Utilizing early cellular changes to explore biological responses to
individual and chemical mixtures
The early cellular changes initiated by external stimuli (whether that be chemical,
physical, or biological agents) can offer a host of information about the adaptive response
and adverse effects related to individual chemical and mixture exposures. Notable
examples of early cellular changes are perturbations of dynamic intracellular signaling
networks and alterations in cellular bioenergetics, such as increased/decreased oxygen
consumption or electron transport chain uncoupling. Due to the interconnectivity of
various effector proteins and biomolecules, activity at a distinct intracellular location can
have consequences at distal locations. Additionally, as the primary tenet of toxicology
proclaims, “it is the dose that makes the poison,” a better understanding of cellular
changes in response to a range of concentrations, especially low dose exposures, is
essential to toxicity testing and chemical risk assessment. Finally, the ability to measure
the rapid and dynamic cellular responses to exposure is critical for an enhanced
understanding of toxicity. The experimental conditions and assays capable of capturing
relevant mechanistic information for toxicity testing will be discussed in this chapter. A
better understanding of the mechanistic components related to chemical response has
numerous implications across many fields, such as risk assessment for toxicology and
target molecule/pathway analysis for drug development and pharmacology. With
mechanistic data collected from various doses, intracellular proteins and biomolecules,
and cellular endpoints, better toxicity prediction models can be developed for individual
chemical and mixtures risk assessment.

3
1.1 Classification of toxic agent and exposure effects - a toxicological perspective
Humans are continuously exposed to a plethora of chemicals daily. These
chemicals can be traced to a variety of sources, such as environmental, pharmaceutical, or
industrial. With the considerable amount of individual chemicals humans can be exposed
to on a daily basis, this begs the question, what classifies a chemical or agent as "toxic"?
A toxic agent, whether it be chemical, biological, or physical, can be classified by their
use (e.g., pharmaceutical, pesticide, additive, etc.), source (e.g., human-made, plant or
animal toxin, etc.), target organ(s) (e.g., brain, liver, heart, etc.), and effects (e.g.,
cardiotoxicity, carcinogenicity, immunogenicity, etc.) (Casarett and Klaassen, 2008). A
primary tenet of toxicology states that all chemical agents are toxic, but it is the dose that
determines if an agent is toxic or safe (Pottenger and Gollapudi, 2009). The classification
of what constitutes an agent as toxic, and the threshold thereof, can be ambiguous.
However, the experimental characterization of an agent that incorporates chemical
properties and biological exposure effects is useful for toxicological risk assessment. The
work described in this dissertation will primarily focus on exogenous chemical stressors,
also known as xenobiotics.
Appropriately characterizing biological effects of a single agent exposure can be
a daunting task. Toxicological risk assessment determines the quantitative estimate of
possible effects of a xenobiotic on human health (Casarett and Klaassen, 2008).
Following exposure, xenobiotic effects can be adverse, deleterious, or dangerous to an
organism (Edwards and Aronson, 2000). Conversely, some effects can be beneficial, such
as pharmaceutical side effects of antihistamines (drowsiness) or oral contraceptives
(decrease acne severity). To properly address the adverse or beneficial nature of a
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chemical exposure, the dose and time course of toxicity/adaptation needs to be
elucidated.

1.1.1 Dose-response for chemical exposure toxicity testing and risk assessment
One of the most central concepts utilized for toxicity studies and risk assessment
is the dose-response relationship (Calabrese and Baldwin, 2003b). The response variable
can be any desired effect to be measured, such as cell death, survival, or cellular oxygen
consumption, and the independent variable would be the doses required to elicit a
response. There are many types of dose-response models used in toxicity testing, but the
most dominant is the threshold model (Calabrese and Baldwin, 2003a). The threshold
model has been used in many scientific disciplines, such as biology, pharmacology, and
toxicology, and has been the primary model for regulatory agencies, such as the U.S.
Federal Drug Administration (FDA) and Environmental Protection Agency (EPA)
(Calabrese and Baldwin, 2003a). In the threshold model, depending upon the effect
measured and assay sensitivity, there exists a dose below which the probability of a
measured response for a sample or individual compared to control is zero (Cox, 1987).
This threshold dose is also referred to as the no observed adverse effect level (NOAEL)
(Allen et al., 1994). An alternative model, the hormesis model, has also proven to be
useful for low-dose (below the NOAEL) risk assessment (Calabrese, 2009) and has seen
a recent surge in interest due to advances in molecular toxicology testing (Calabrese and
Baldwin, 2003b). The hormesis model is a biphasic dose-response relationship and can be
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succinctly described as low dose activation followed by high dose inhibition, which can
appear as a U-shaped or J-shaped dose-response curve (Calabrese, 2008).
The renewed interest in hormesis as a valid model for toxicity testing has opened
the door for low-dose biochemical and molecular toxicology research (Calabrese, 2008).
It is important to note that the hormetic dose-response should also consider time in
toxicity testing. This is due to the fact that hormesis responses may be a compensatory
response that follows the initial disruption in homeostasis, resulting in the characteristic
low-dose stimulatory response (Calabrese, 2001). Biological systems are highly
coordinated and dynamic (Kholodenko et al., 2010), the exclusion of temporal response
in risk assessment modeling would ignore the ability of an organism to adapt and respond
to a low-dose exposure. Therefore, toxicological risk assessment needs to be inclusive of
the spatiotemporal aspect of biological response post-exposure as well as a wide range of
doses, including low doses.

1.1.2 Chemical mixtures
Current chemical exposure risk assessment is primarily carried out for single
xenobiotics (Cedergreen et al., 2008), however, in reality humans are continuously
exposed to a vast number of components, whether they be chemical, physical, or
biological agents, at various doses, and through a variety of exposure routes on a daily
basis (Groten et al., 2001). Understanding and ultimately predicting the possible
combined effects of a given mixture exposure is necessary for risk assessment
toxicology. There are two types of mixtures: simple and complex. Simple mixtures
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contain a small number of different chemicals and the composition is known. Complex
mixtures contain hundreds to tens of thousands individual chemicals, of which the
composition (dose or constituents) is not known (Feron et al., 1998). Experimentally
determining the effects of all possible mixture combinations, or even binary mixtures, for
a range of doses at different time points is not physically or financially possible
(Cedergreen et al., 2008). Therefore, adequate models capable of predicting mixture
responses are necessary for various sectors, such as pharmacological adverse interaction
risk assessments and environmental exposure risk assessments. The two most commonly
used and accepted mixture prediction models are Loewe additivity (dose addition) and
Bliss independence (response addition) (McCarty and Borgert, 2006).
Dose addition is typically used when two or more chemical agents have a
similar mechanism of action (Borgert et al., 2004). Dose addition is based on the theory
that two chemicals in a mixture act as a dilution of each other (Loewe and Muischnek,
1926; Berenbaum, 1989). Traditional dose additivity can be described as shown in
Equation 1:

(1)

where α' is the dose of the chemical

when administered as a mixture producing

response E, and α is the concentration of the chemical agent, , required to produce the
response effect E when administered alone (single exposure). Equation 1 can be used for
n number of agents as a mixture. If the overall expression is < 1, the mixture is
considered synergistic. Conversely, if the overall expression is > 1, the mixture is
considered antagonistic (Rajapakse et al., 2001).
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Response addition (Bliss independence) is typically used for two (or more)
chemicals that do not have the same mechanism of action, that is, the organism will
respond to each chemical agent independently, as though the other agent(s) are not
present (Bliss, 1939; McCarty and Borgert, 2006). The prediction of mixture effects
using response addition is equivalent to the conditional sum of independent chemical
effect probabilities (Boyd et al., 2011). Response addition can be described by the
expression (equation 2)
(2)
where F( ) is the response effect produced by chemical

at dose α. Since this is a

probabilistic model, F( ) cannot be greater than 1. Dose addition and response addition
models are generalizations of nonlinear regression models, such as a Gompertz growth
curve or Hill plot, and can be easily compared to observed mixture dose-response curves
(Rajapakse et al., 2001; Boyd et al., 2011).

1.1.3 Mode of action vs mechanism of action
Regulatory guidelines for mixture risk assessments rely heavily on the similarity
(or dissimilarity) of two chemical components' mechanistic information for model
selection of a given mixture (USEPA, 1986; USEPA, 1999; USEPA, 2000; ATSDR,
2001b; ATSDR, 2001a; USEPA, 2002). In this discussion of prediction models for
mixture toxicity, the term “mechanism of action” is used loosely. The term "mechanism"
of action is often used interchangeably with "mode" of action (Borgert et al., 2004).
However, these terms have specific definitions, but are often defined differently
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depending upon the literature article cited (Aptula and Roberts, 2006; Spurgeon et al.,
2010). Traditionally, "mechanism of action" refers to the series of molecular events from
the absorption of an effective dose of an agent to the eventual biological response
(Butterworth et al., 1995). To fully describe the mechanism of action for a chemical, the
components outlined in Figure 1.1 would need to be determined experimentally.

Figure 1.1. Mechanism of action. Schematic outlining the components necessary to
elucidate the mechanism of action for an exposure. All steps must include the temporal
and dose components to fully understand mechanism of action for a given chemical or
mixture exposure.

The term "mode of action" is a more generalized way to describe a chemical's
action on a given organism (Schlosser and Bogdanffy, 1999). The term "mode of action"
describes the type of observed response of an organism exposed to a given chemical or
mixture and may only refer to the significant events or components of the mechanism
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necessary for producing a particular biological response or toxic effect (Dellarco and
Wiltse, 1998). Regardless of the terminology, the suitability of either model for a given
experiment or effect prediction remains debatable when thorough mechanisms or modes
of action are unknown, especially for low dose studies (Jonker et al., 2005; Spurgeon et
al., 2010). Often, the models fail to predict mixtures toxicity when an observed mixture
acts synergistically (Meled et al., 1998; Forget et al., 1999), antagonistically (Posthuma
et al., 1997; Van Gestel and Hensbergen, 1997), or dose-dependent subtle interactions
(e.g., synergy for low dose mixtures and antagonist for high dose mixtures) (Gennings et
al., 2002; Jonker et al., 2004). To address these challenges, future model development
should incorporate low dose (i.e., below the NOAEL) mixtures mechanistic effects on the
appropriate spatiotemporal scale.

1.2 Early cellular changes post-exposure
Understanding and ultimately predicting potential biological effects and health
outcomes from single chemical or mixture exposure remains an arduous task for risk
assessment. The predominant approach for toxicity testing relies heavily on whole animal
studies evaluating observable apical responses, such as clinical effects or pathologic
changes from high dose exposures (Spurgeon et al., 2010). While many of these studies
have been thorough, the amount of time and resources required to carry out this lowthroughput methodology has left this approach unable to meet the demands of current
toxicology needs (NRC, 2007). The enormous backlog of chemicals waiting to be
evaluated for toxic outcome has inspired a paradigm shift in toxicity testing, proposed by
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the U.S. National Research Council (NRC) report, Toxicity Testing in the 21st Century: A
Vision and a Strategy (NRC, 2007; Bhattacharya et al., 2011). The NRC proposed a
transition from in vivo low-throughput animal toxicity testing to an in vitro highthroughput approach utilizing well-designed mechanistic information-based assays. This
in vitro approach would take advantage of early cellular perturbations post-exposure
associated with toxicity endpoints in human cell lines and tissues to elucidate mechanistic
information regarding the mode(s) of action for a potential xenobiotic or mixture (AtteneRamos et al., 2013). Additionally, the high-throughput nature of this approach would
allow for testing on a wide range of doses, especially low doses, which is not currently
possible with traditional whole animal studies (Bhattacharya et al., 2011). New risk
assessment approaches would include a suite of assays in order to cast a wide net on early
cellular changes, such as changes in cellular bioenergetics, and various pathway
perturbations, such as alterations in post-translational modifications post-exposure, to
fully understand the cellular response, whether that be adaptation after exposure to a new
homeostatic state, or cell death (Andersen and Krewski, 2009).
Recent advances in systems toxicology have opened the door for the collection
and analysis of large amounts of mechanistic data across a wide dosing range and time
scale. Incorporating toxicodynamic factors for risk assessment can aid in our
understanding of xenobiotic toxicity. The term toxicodynamics can be succinctly
described as what the toxicant does to the body. Toxicodynamic analyses interrogate the
spatiotemporal interaction of a xenobiotic with biological targets, the corresponding
disruption of molecular pathways and bioenergetics, and downstream effects after
exposure (Boelsterli, 2007).
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Marrying toxicokinetic and toxicodynamic approaches for risk assessment can
offer a wealth of knowledge regarding xenobiotic exposure and the biological
perturbations

associated

with

exposure and their corresponding
effects (Figure 1.2). Perturbations
of

biological

processes

by

xenobiotic exposure can elicit
early cellular changes, leading to
an adaptive stress response for

Figure 1.2. Early cellular changes related to biological
outcome. Toxicokinetic components of exposure involve
the absorption of the chemical exposure, biotransformation,
and distribution resulting in the tissue dose. The chemical
then interacts with molecular targets, perturbing
endogenous pathways and processes, resulting in early
cellular changes, which contributes to the toxicodynamic
response post-exposure. Early cellular changes can lead to
adverse effects (toxicity) or adaptive response and survival.
Adapted from Andersen et al. (2005). Reprinted with
permission from Elsevier.

continued survival or adverse
response

leading

to

toxicity

(Andersen, 2010). Early cellular
changes

corresponding

toxicodynamics
highlighted

in

will
this

to
be
work,

specifically intracellular signaling perturbations (e.g., post-translational modifications
after chemical exposure) and alterations in cellular bioenergetics.

1.2.1 Intracellular signaling perturbations associated with exposure
The

toxicodynamic

components

of

early

cellular

changes,

biological

perturbations, and corresponding response yield valuable mechanistic information for
toxicity risk assessment. Early and late effects associated with chemical exposure are
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mediated by plasma membrane receptor proteins acting as a sensor and their downstream
signaling pathways (Bhattacharya et al., 2011). Signaling pathways are not static linear
pathways that simply transmit signals, but are responsible for encoding and integrating
both internal and external cues (Kholodenko, 2006). Exposure to chemical insults can
perturb the dynamic and highly coordinated signaling pathways responsible for normal
biological function and maintenance (Houck and Kavlock, 2008). Additionally, chemical
insult at one molecular target and pathway can propagate throughout the signaling
network due to pathway crosstalk and the interconnectivity of various signaling cascades
(Kholodenko et al., 2010). As such, cellular spatiotemporal signaling dynamics are
responsible for integrating and interpreting intra- and extracellular cues to make cellular
fate decisions, such as proliferation, differentiation, or programmed cell death (apoptosis)
(Murphy et al., 2004; von Kriegsheim et al., 2009; Kholodenko et al., 2010).
Signaling networks are primarily regulated by post-translational modifications
(PTMs). PTMs are vital to signaling coordination and diversification of proteins for
various functions (Wold, 1981; Aye-Han et al., 2009). PTMs can modify proteins after
translation via complex molecules (glycosylation and isoprenylation), peptides or
proteins (ubiquitylation and sumoylation), chemical groups (acetylation, methylation, and
phosphorylation), and cleavage (proteolysis) (Wang et al., 2014). The rapid
toxicodynamic response of cells to xenobiotics is primarily coordinated by signal
transduction networks, which follow a simple framework: the phosphorylation /
dephosphorylation cycle mediated by kinases and phosphatases (Kumar et al., 2007;
Schilling et al., 2009). Kinases are intimately involved in the regulation of signaling
events relevant to cellular death and survival processes (Bononi et al., 2011). Xenobiotics
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can interfere with kinase signaling via activation (e.g., overstimulation) or inhibition
(Boelsterli, 2007). Kinases can be activated/deactivated via the addition or removal of a
phosphate group at serine, threonine, and tyrosine residues (-OH containing amino acids)
(Wold, 1981), shown in Figure 1.3.

Figure 1.3. Mechanism of phosphorylation. This reaction scheme
uses serine as the example residue, however, this mechanism is true
for tyrosine and threonine phosphorylation as well.

The phosphorylation/dephosphorylation of a protein acts as a molecular switch to
activate or deactivate a protein. In the catalytic domain of protein kinases, the -OH group
on serine, threonine, and tyrosine residues act as a nucleophile, attacking the γ-phosphate
on adenosine triphosphate (ATP) resulting in the transfer of a phosphoryl group to the
protein (Endicott et al., 2012). In this scheme, magnesium is a critical component for
protein phosphorylation, acting as a supportive chelator. The covalent bonding between
phosphate groups and protein kinases typically induce a conformational change, aiding or
preventing protein-protein (enzyme-substrate) interactions (Wang et al., 2012). It is this
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protein-protein/enzyme-substrate interaction where critical cellular information can be
transmitted throughout the signaling network.
Under xenobiotic stress conditions, many pathways can be perturbed, including
survival and death pathways. The three major stress-activated pathways are the mitogenactivated protein kinase (MAPK) pathway (also commonly referred to as extracellular
signal-regulated kinases (ERK) pathway), the stress-activated protein kinase (SAPK)
pathway (also commonly referred to as jun N-terminal kinase (JNK) pathway), and the
p38 pathway (Paul et al., 1997; Tibbles and Woodgett, 1999; Pouyssegur et al., 2002).
These stress pathways are endogenously active, controlling cellular fate via
transcriptional activation and/or inhibition of genes regulating survival/proliferation and
cell death (Boelsterli, 2007). These pathways were traditionally thought of as discrete
linear signaling cascades; however, it is now well known that they are merely
components of a dynamic and highly interconnected network of pathways that contain
many crosstalk, feedback and feedforward mechanisms to adequately and efficiently
response to stress-inducing stimuli (Junttila et al., 2008; Kholodenko et al., 2010).
Therefore, it is the delicate balance/imbalance of these pathways that decides the cell's
ultimate fate (Bononi et al., 2011; Currie et al., 2014). The highly dynamic and
interconnected nature of signaling networks has made it increasingly difficult to elucidate
and predict network responses to xenobiotic stress. However, advances in computational
and network biology, high-throughput experimental techniques, such as -omics
investigations using mass spectrometry, multiplex bead-based ELISA (enzyme-linked
immunosorbent assay) suspension array systems, and microchip arrays, and public
databases have greatly improved signaling research. With these advances, new
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toxicological risk assessment approaches for determining potential toxic outcome of a
xenobiotic or mixture using mechanistic information can be attempted, as postulated by
the NRC report (NRC, 2007).

1.2.2 Bioenergetic changes post-exposure
Kinase signaling is an energy demanding process, and its reliance on
phosphorylation results in the consumption of substantial amounts of available adenosine
triphosphate (ATP) (Hammerman et al., 2004). ATP-production governs ATP-consuming
processes, such as signal transduction in mammalian cells, and this production is
primarily driven by oxidative phosphorylation within mitochondria (Buttgereit and
Brand, 1995; Ainscow and Brand, 1999). Mitochondria are the energy production hub of
a cell via production of ATP via phosphorylation and, of equal importance, key mediators
in kinase signal transduction, regulating cell survival, proliferation, differentiation, and
death (Hammerman et al., 2004; Mohamed et al., 2014). Due to their critical role in many
cellular processes, mitochondria are also susceptible to xenobiotic exposure effects.
Additionally, irreversible processes leading to cell death primarily rely on two
mitochondria-related phenomena: 1) the inability to reverse mitochondrial dysfunction,
resulting in ATP depletion and 2) the disturbance of membrane function (both
mitochondrial membrane and plasma membrane) (Law and Elmore, 2008). Therefore,
maintenance of mitochondrial bioenergetics and integrity is critical to cellular fate.
Mitochondria are comprised of several key features: the outer mitochondrial
membrane, intermembrane space, inner mitochondrial membrane, and matrix (Figure
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Figure 1.4. Mitochondria. The two membranes of mitochondria are shown above as the outer
membrane (OM) and inner membrane (IM). The VDAC transmembrane protein is shown in yellow at
the OM and ANT transmembrane protein is in teal at the IM to illustrate the shuttle of ATP from ATP
synthase (also known as Complex V) of the ETC to the cytosol. Small blue dots indicate cytochrome c
within the intermembrane space and roman numeral cartoons indicate ETC subunits. Adapted from
Desagher and Martinou (2000), reprinted with permission from Elsevier.

1.4). The outer mitochondrial membrane is permeable to small molecules (molecular
weight < 5,000 g/mol) and ions, which readily diffuse through transmembrane porin
proteins, such as voltage-gated anion channel (VDAC) (Ninomiya-Tsuji, 2008). The
inner membrane, however, is impermeable to most molecules and ions, including protons
and ATP (Lehninger et al., 2008). The inner membrane contains the proteins that make
up the electron transport chain (ETC). Additionally, the inner membrane contains
numerous transport proteins to allow metabolites to pass through into the matrix and to
export ATP generated by the electron transport chain (ETC) into the intermembrane
space (Ninomiya-Tsuji, 2008). The space between the two membranes is called the
intermembrane space. The intermembrane contains a small heme-containing protein
called cytochrome c within the intermembrane-side of inner membrane folds (referred to
as intracristae space), which acts as an electron carrier for Complex III on the ETC, and
when released from the outer membrane, can initiate caspase-dependent apoptosis
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(Desagher and Martinou, 2000; Kroemer et al., 2007). The protein adenine nucleotide
translocase (ANT) is the transporter responsible for shuttling ATP from the matrix to the
intermembrane space (Ninomiya-Tsuji, 2008). Additionally, ANT forms a complex with
VDAC (an outer mitochondrial membrane transporter), commonly referred to as the
permeability transition pore (PTP) that can compromise the impermeability of the
mitochondrial membranes. If the PTP is open, an influx of ions and water can bombard
the matrix, causing swelling, loss of membrane potential, and uncoupling of oxidative
phosphorylation, eventually leading to cell death (Fosslien, 2001). Finally, the matrix,
which is in the space contained by the inner membrane, houses all energy-yielding
oxidative reactions, such as the citric acid cycle, fatty acid oxidation, and the ETC
(Ninomiya-Tsuji, 2008). The matrix also contains important ions (magnesium, calcium,
and potassium), metabolic intermediates, ATP/ADP, and mitochondrial DNA.
Mitochondrial DNA genes are transcribed and translated within the matrix as well.
The number of mitochondria in each eukaryotic cell can vary depending upon the
cell type. Red blood cells (erythrocytes) do not have mitochondria, however, the heart,
kidney, and liver are considered mitochondria-rich (Veltri et al., 1990). Mitochondriarich cell types are especially sensitive to xenobiotics that target the ETC. There are two
classes of ETC inhibitors: 1) xenobiotics that block the transport of electrons via binding
to ETC enzyme complexes (e.g., deguelin binding to Complex I) and 2) xenobiotics that
stimulate the flow of electrons at one portion of the ETC, but shunt electrons away from
their normal route by acting as an electron acceptor. Disruption of normal ETC function
and mitochondrial bioenergetics can have deleterious effects (both acute and chronic) on
the target tissue as well as whole organism. Examples of pathological conditions where
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mitochondrial dysfunction plays a critical role are neurodegenerative diseases,
neurotoxicity, heart disease (myocardial infarction and atherosclerosis), liver injury
(ischemic injury and cholestasis), obesity, and cancer (Kroemer et al., 2007; Nunnari and
Suomalainen, 2012). Thus, mitochondrial bioenergetics should be carefully considered
and included in toxicity risk assessment.

1.2.3 Timescale of exposure effects
The toxicity of a xenobiotic or mixture at their intended molecular/tissue target(s)
can vary over exposure time and any change is commonly known as time-dependent
toxicity (Dawson et al., 2014). The initial toxicodynamic response to any xenobiotic or
mixture exposure is predominantly coordinated by signal transduction networks, which
can initiate response within the first few seconds to minutes of exposure. The time course
from initial toxicodynamic response(s) to cell death following exposure can have a vast
range (Rehm et al., 2009). For example, the time delay between xenobiotic exposure and
execution of apoptosis can take from several hours to over a day (Lemasters et al., 1998;
Messam and Pittman, 1998). With this in mind, monitoring early cellular changes that
contribute to adaptive stress response (survival and new homeostatic state) or lead to
adverse effects (apoptosis, carcinogenicity) may aid toxicological understanding and
ultimately the prediction of potential adverse effects from xenobiotic or mixture
exposures.
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1.3 Experimentally testing early cellular changes that may contribute to exposure
sensing and response
Traditional risk assessment testing techniques involve screening potential agents
using in vivo and in vitro endpoint experiments, such as neurotoxicity or developmental
toxicity, and mode of action analysis, such as cytotoxicity or mutagenicity (Dix et al.,
2007). However, the recent paradigm shift charged by the NRC report has initiated a new
chemical risk assessment approach that utilizes high-throughput in vitro screening assays
to exploit early cellular changes (such as signaling pathway perturbations and alterations
in cellular bioenergetics) to reveal mechanistic information about adverse or adaptive
effects after xenobiotic exposure.

1.3.1 In vitro cell culture
The large number of potential toxic chemical agents that have yet to be fully
characterized pose a significant problem for risk assessment testing (NRC, 2007).
Traditional in vivo methods cannot be solely relied on for risk assessment testing due to
the low-throughput, high financial and time cost, and the sheer number of animals
necessary to test the thousands of chemicals yet to be evaluated. Further, the utility of
mechanistic information from animal studies has been questionable due to disappointing
cross-species extrapolation for real life low dose human exposure effects (Houck and
Kavlock, 2008). Thus, a paradigm shift from traditional in vivo methods to an in vitro
approach utilizing assays to collect mechanistic information for pathway/network
analyses and eventual prediction modeling with computational toxicology has been
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initiated by the NRC report (NRC, 2007). The NRC suggested human in vitro highthroughput screening assays to measure early cellular effects, such as perturbations of
critical signaling pathways related to survival and death (referred to as potential adverse
outcome pathways by the NRC), across a wide dosing range and multiple cell lines, both
immortalized and primary cell culture (Andersen et al., 2010).
The paradigm shift from traditional in vivo animal studies to new in vitro highthroughput screening assays using human cell lines raises some new questions. What cell
type should be used (immortalized vs primary)? Primary cell culture is culture that is
initiated immediately following tissue extraction from the sample organism. Once the
cells reach confluency (typically 80 % of the culture-containing flask covered by cells,
without overlapping each other), cells need to be subcultured (also known as passaging)
by dividing the cells into multiple culture flasks for continued growth. Primary cell
culture can typically only be subcultured several times before they can no longer be used.
On the other hand, immortalized (continuous) culture is when cells are cultured for a
theoretically infinite number of subcultures, which is achieved via transformation
(spontaneously transformed

via

cancerous

cell

lines

or

chemically induced

immortalization). Immortalized/continuous cell lines offer a low cost, reproducible in
vitro experimental set-up, but may result in disparate responses than those achieved in
primary culture or in vivo due to their continuous cell cycle progression. Even though the
response may be slightly different from immortalized to primary or in vivo studies, useful
mechanistic information can be collected for toxicity risk assessment. Fortunately, there
are several cell lines commercially available that have libraries of data, such as HepG2
(human hepatocellular carcinoma) for liver toxicity (O'Brien et al., 2006), MCF-7
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(human breast cancer) for estrogen responsive toxicity studies (Holliday and Speirs,
2011), and HEK293 (human embryonic kidney cells) for kidney toxicity (Sasaki et al.,
2007).
Liver injury and toxicity due to xenobiotic exposure is a major concern for
pharmaceutical regulatory and toxicological risk assessment (Kavlock et al., 2012).
Additionally, the liver plays a vital role in xenobiotic biotransformation after exposure
(Mersch-Sundermann et al., 2004). Thus, in vitro high-throughput approaches using
human-derived liver cell lines to probe important early cellular exposure effects and
potential pathway perturbations are necessary for toxicological risk assessment. The U.S.
EPA ToxCast research program was initiated to screen previously untested environmental
chemicals for adverse effects using a large number of high-throughput bioassays. Data
collected from ToxCast assays is made available through the ToxCast data library to
disseminate chemical exposure profiles to further toxicology research and gain a
mechanistic understanding of chemical exposure (Sipes et al., 2013). The ToxCast library
has two liver models for toxicity testing: primary rat hepatocytes and HepG2 cells
(Kavlock et al., 2012). Both models offer important information about hepatotoxicity.
Due to the limited availability of human primary liver cells, rat primary hepatocytes are
often used for hepatotoxicity risk assessments. Previous studies have shown that
xenobiotic metabolizing enzymes have significant interspecies variation (Selkirk, 1977;
Maslansky and Williams, 1982). An accepted alternative to primary rat hepatocytes for
liver toxicity research is the HepG2 cell line. A benefit of using HepG2 vs primary rat
hepatocytes is that they are human-derived. Most importantly, the HepG2 cell line retains
endogenous xenobiotic metabolizing enzymes, whereas primary hepatocyte culture
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typically loses these vital enzymes (Knasmuller et al., 1998).

The in vitro studies

discussed in Chapters 2 - 4 use the HepG2 cell line as the model system for several
xenobiotic exposure proof-of-principle approaches.

1.3.2 Real time in vitro assays to measure early cellular changes
As discussed previously, initial cellular responses to xenobiotic exposure are
rapid, dynamic, and highly integrated for determining eventual cellular fate. Assays
capable of capturing these dynamic processes and relating them to apical outcomes (cell
death, survival, plasma membrane degradation) are necessary for xenobiotic risk
assessment predictions. The real-time assays used in this dissertation are related to
mitochondrial bioenergetics (reduced form of nicotinamide adenine dinucleotide
(NADH) production, cellular oxygen consumption, and estimations of ATP from NADH
and oxygen consumption) and cell death (plasma membrane degradation).

1.3.2.1 Mitochondrial bioenergetics assays: NADH generation and oxygen consumption
NADH is a vital component of mitochondrial function, energy metabolism and
oxidative stress (Ying, 2008). As a critical component of the ETC and bioenergetics,
early cellular effects and perturbations can be monitored via changes in cellular NADH.
One of the most useful and remarkable features of NADH is that it strongly absorbs at
340 nm; therefore, real time kinetic measurements of cellular NADH can be obtained
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without the assistance of any fluorescent tag or probe (McComb et al., 1976; Vrana et al.,
2014).
Intracellular molecular oxygen is a key component of cellular homeostasis and
mitochondrial oxidative phosphorylation via the ETC. After xenobiotic exposure, early
cellular changes associated with mitochondrial bioenergetics and cellular respiration can
be monitored using real-time oxygen consumption assays. Determining key time points
related to perturbations in cellular respiration can further the mechanistic understanding
of xenobiotic exposure and eventual cell survival/death. High-throughput real-time assays
for oxygen consumption that do not perturb endogenous intracellular activity are limited.
The most popular method for cellular oxygen consumption is the Clark electrode,
however it is a very low-throughput method (one sample at a time) (Diepart et al., 2010).
The development of oxygen sensitive extracellular probes that can reproducibly measure
discrete changes in oxygen consumption over time (with comparable sensitivity to the
Clark electrode) have significantly advanced mitochondrial and toxicological research.
Once such probe was developed by Luxcel Corp (Cork, Ireland), manufactured as
MitoXpress. The MitoXpress probe is an extracellular phosphorescent platinumcoproporphyrin dye with a long emission time and stable phosphorescent signal that can
be used for 24 hour kinetic measurements in a 96-well plate format, making it highthroughput (Dmitriev et al., 2010). For this assay, the MitoXpress probe is quenched by
molecular oxygen (O2). A decrease in extracellular O2 concentration (increase in cellular
oxygen consumption) is measured as an increase in signal (less probe is quenched by O2),
whereas an increase in extracellular O2 concentration is measured as a decrease in signal
(more O2 to quench the probe; less oxygen is consumed by the cell) (Diepart et al., 2010).
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Finally, one of the most critical components of bioenergetics, ATP can be
measured to monitor cellular perturbations after xenobiotic exposure. Previously, assays
for intracellular ATP have employed fluorescent tags, which can potentially disrupt
endogenous intracellular activity (e.g., FRET) (Berg et al., 2009), or involve cell lysis
(e.g., luciferase assay), making real-time in vitro ATP measurements not possible
(Imamura et al., 2009). Monitoring relative ATP generation in response to chemical
insult without potentially disrupting sensitive intracellular activity is imperative. To this
end, the Boyd Lab has developed an extracellular approach to estimate ATP production
with data collected from real-time oxygen consumption and NADH production assays.
These data sets allow for stoichiometric determinations of ATP production in real-time.
Theoretically, mitochondrial oxidative phosphorylation is responsible for producing a
substantial portion of cellular ATP, and traditionally, NADH and oxygen are related to
ATP production as shown below (Kadenbach, 1986; Lehninger et al., 2008):

1
1 NADH  O2  3 ATP (1)
2
Since our MitoXpress assay monitors oxygen consumption, the equation can be doubled:

2 NADH  O2  6 ATP (2)
Additionally, cells can produce ATP via glycolysis, where 1 ATP is generated for each
available NADH. This may be particularly true for HepG2 cells, since many cancer cells
have been shown to have a high reliance on glycolysis due to the Warburg effect
(Warburg, 1956; Vander Heiden et al., 2009). To account for ATP production when there
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is limited or no oxygen, an “if then else loop” was used to calculate theoretical ATP
generation:

If 6  [O2 ] sample  2  [ NADH ] sample  0;
Then
Else

[6  [O2 ] sample ]  [2  [ NADH ] sample ]
4
[ NADH ] sample
4

This method has proven successful for two disparate xenobiotics, demonstrating a strong
correlation to relative ATP measurements collected via the luciferase assay (Vrana et al.,
2014).

1.3.2.2 Plasma membrane degradation
The "point-of-no-return" for which a cell decides to die has yet to be determined
(Kroemer et al., 2005). However, certain cellular features implicate a cell has died; one
such feature is the loss of plasma membrane integrity (Kroemer et al., 2005). A simple,
reproducible, and high-throughput assay for plasma membrane degradation is the
ethidium homodimer-1 (EthD-1) assay, commonly referred to as a "dead assay." The
EthD-1 dye is impermeable for cells with an intact plasma membrane. However, when
the plasma membrane is permeabilized, the EthD-1 can penetrate the cell and intercalate
with DNA nucleic acids. When EthD-1 is bound to strands/segments of DNA, the dye
emits a strong red fluorescence, whereas in the absence of available DNA segments, the
dye has a very low intensity fluorescent signal (Grogan et al., 2002). This dye is not only
useful for in vitro plate reader-based assays, but also fluorescence microscopy.
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1.3.3 Endpoint in vitro assays to measure early cellular changes and long term exposure
effects
The previous assays described are best suited for in vitro, real-time kinetic
measurements using a high-throughput platform, such as 96+ well plate assays. However,
assays that require cell lysis or disruption of cellular function are commonly referred to as
endpoint assays. The high-throughput in vitro endpoint assays used in this work are MTT
(cell viability), luciferin/luciferase (intracellular ATP), and multiplex bead-based ELISA
(phosphoprotein or cytokine).

1.3.3.1 Viability
There are several viability measurements used for in vitro experiments that are
cheap, easy to use, and high-throughput. Examples include the lactate dehydrogenase
(LDH) assay, neutral red, and methyl tetrazolium (MTT) assay. There are benefits and
drawbacks for each method, however, of the three, neutral red and MTT are the most
sensitive for cell viability (Fotakis and Timbrell, 2006). While all three assays are used to
determine viability, most are used as an orthogonal measurement of cytotoxicity (i.e., not
used alone), or for initial screening of appropriate dosing ranges (Galluzzi et al., 2009).
The only true assays for cell death measure plasma membrane degradation, such as the
EthD-1 dye. However, due to its low cost, robustness, and ease of use, MTT is commonly
included in studies to estimate viability. The MTT reagent, 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide, is a yellow water soluble salt that is converted into
insoluble formazan crystals in the presence of succinate dehydrogenase within the
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mitochondria of metabolically active cells via cleavage of the tetrazolium ring (Fotakis
and Timbrell, 2006). The insoluble purple formazan crystals can be solubilized by DMSO
or detergent for quantification via absorbance using 96-well plate spectrophotometry.

1.3.3.2 Intracellular ATP
As described previously, ATP is a critical biomolecule for cell survival. While
real-time assays for ATP generation are limited, endpoint assays for ATP are widely used
and extremely sensitive (Imamura et al., 2009). Additionally, ADP:ATP ratios have been
used to measure cell viability, apoptosis, and necrosis (Bradbury et al., 2000). The
predominant endpoint ATP assay is the D-luciferin-luciferase assay, which requires cell
lysis for in vitro applications. The luciferase assay is a bioluminescent assay where the
substrate D-luciferin is converted into oxyluciferin, by the luciferase enzyme in the
presence of ATP. The conversion from luciferin to oxyluciferin emits a stable, relatively
long-lived light emission (~30 minutes). This assay is very sensitive, ranging from 10 -13
mol to > 10-6 mol ATP, and can be used for a wide variety of sample matrices, such as
soil, milk, plasma, and cell culture (Kricka, 1988).

1.3.3.3 Multiplex bead-based suspension array
The analysis of key signal transduction perturbations via PTM assays is one of the
most valuable tools for intracellular exposure mechanism-based risk assessment. Upon
insult by a xenobiotic, the cellular toxicodynamic response is coordinated by signal
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transduction networks, which follow a rudimentary framework, the phosphorylation /
dephosphorylation cycle mediated by kinases and phosphatases (Kumar et al., 2007;
Schilling et al., 2009). Traditionally, western blot and immunoprecipitation have been the
assays of choice for phosphoprotein analyses (Schmelzle and White, 2006). While
western blotting has been the gold standard for phosphoprotein determinations, it is very
low throughput. A multiplexed and high-throughput assay for phosphoprotein analysis to
elucidate network perturbations and mechanistic exposure information is the bead-based
(microsphere) sandwich-based ELISA, developed by Luminex (Poetz et al., 2010). This
assay is a modification of a traditional ELISA, whereby the capture antibody (Ab) is
immobilized to magnetic (or non-magnetic) polystyrene microspheres (Figure 1.5).

Figure 1.5. Bead-based ELISA. A microsphere, which can be magnetic or non-magnetic, (shown in
red) has two fluorescent dyes (excited by the same wavelength of light but emit different
wavelengths) encapsulated within the bead. These dyes act as the bead recognition element, and the
ratio of dyes identifies the bead type (e.g., bead region 1 has a ratio of 1:100 for the two dyes, and this
region has the Ab for ERK protein immobilized on the surface). The assay proceeds as a traditional
sandwich ELISA (with the exception that the capture Ab is immobilized to a microsphere) where the
capture Ab is specific for one of your desired analytes (e.g, anti-ERK Ab is selective for ERK
protein) and the biotinylated detection Ab recognizes a separate epitope of your desired analyte (e.g.,
anti-phosphoERK Ab to recognize phosphorylated ERK). The biotinylated detection Ab then binds
with the fluorescent reporter, streptavidin-phycoerythrin (due to the extremely high binding affinity of
biotin for streptavidin). Antibody, Ab; phycoerythrin (PE).

29
The assay workflow proceeds as follows: 1) capture Ab beads are added to the
assay plate wells 2) add the analyte(s)-containing sample and incubate 3) add biotinylated
detection Ab and incubate 4) add fluorescent reporter (e.g., streptavidin-phycoerythrin
complex) and incubate 5) analyze samples via suspension array (Houser, 2012).
Since this is a multiplex method, 100+ different Ab-bead combinations can be
assayed per well. The beads are coded with two dyes that can be excited by the same
wavelength but emit different wavelengths. Depending upon the ratio of the two
encapsulated dyes, the bead region (code) can be measured by the instrument. In order to
differentiate between bead dyes and fluorescent reporter dye, the suspension array
platform utilizes a duel laser system: a red solid state laser (635 nm) to excite dyes
encapsulated within the microspheres for bead type identification and a Nd:YAG laser
(532 nm) to excite the phycoerythrin dye (fluorescent reporter). The fluorescent reporter
is bound to the analyte-bead complex (shown in green, Figure 1.5) for quantitation of the
captured analyte (Houser, 2012). All emission intensities are detected with a
photomultiplier tube. This method is high-throughput and requires low sample volume.
Currently, Luminex-manufactured magnetic microspheres (sold under the name
MagPlex) have 500 unique bead regions, allowing for 500 different antibody assays to be
performed per well of a 96-well plate (Luminex, 2015).
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2. Forecasting cell death dose-response to single chemicals in vitro1
The rapid pharmacodynamic response of cells to toxic xenobiotics is primarily
coordinated by signal transduction networks, which follow a simple framework: the
phosphorylation / dephosphorylation cycle mediated by kinases and phosphatases.
However, the time course from initial pharmacodynamic response(s) to cell death
following exposure can have a vast range. Viewing this time lag between early signaling
events and the ultimate cellular response as an opportunity, we hypothesize that
monitoring the phosphorylation of proteins related to cell death and survival pathways at
key, early time-points may be used to forecast a cell's eventual fate, provided that we can
measure and accurately interpret the protein responses. In this paper, we focused on a
three-phased approach to forecast cell death after exposure: 1) determine time-points
relevant to important signaling events (protein phosphorylation) by using estimations of
ATP production to reflect the relationship between mitochondrial-driven energy
metabolism and kinase response, 2) experimentally determine phosphorylation values for
proteins related to cell death and/or survival pathways at these significant time-points,
and 3) use cluster analysis to predict the dose-response relationship between cellular
exposure to a xenobiotic and plasma membrane degradation at 24 hours post-exposure.
To test this approach, we exposed HepG2 cells to two disparate treatments: a GSK-3β
inhibitor and a MEK inhibitor. After using our three-phased approach, we were able to
accurately forecast the 24 hour HepG2 plasma membrane degradation dose-response

1

Parts of this chapter have been published previously, either in part or in full, from Vrana, J.A., Currie,
H.N., Han, A.A., Boyd, J. (2014) Forecasting cell death dose-response from early signal transduction
responses in vitro. Toxicol Sci. 140, 338-351. Reproduced with permission from Oxford University Press.
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from protein phosphorylation values as early as 20 minutes post-MEK inhibitor exposure
and 40 minutes post-GSK-3β exposure.

2.1 Introduction
In mammalian systems, the cellular response to toxic xenobiotics involves the
complex, yet coordinated transmission of intracellular signaling molecules to determine a
cell's eventual fate (i.e., survival or death) (Kumar et al., 2007; Schilling et al., 2009).
The initial pharmacodynamic response to any xenobiotic exposure is predominantly
coordinated by signal transduction networks, which can initiate response within the first
few seconds to minutes of exposure. This response follows a simple framework: the
phosphorylation and dephosphorylation cycle of proteins mediated by kinases and
phosphatases (Kholodenko, 2006; Newman et al., 2013). However, the time course of
cell death from exposure to visual morphological changes can have a vast range. For
example, the time delay between xenobiotic exposure and execution of apoptosis can take
from several hours to over a day (Lemasters et al., 1998; Messam and Pittman, 1998).
Based upon the time delay between these early and late responses, we hypothesize that
monitoring the phosphorylation of proteins related to cell death and survival pathways
may be predictive of a cell's eventual fate, provided that we can read and correctly
interpret the protein responses.
Considering the vast number of proteins involved in critical intracellular signaling
processes, the number and type of proteins to be monitored for forecasting a cell's fate
must be judiciously selected. An advantageous group of proteins to monitor for this
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approach are kinases involved in the regulation of signaling events relevant to cellular
death and survival processes. Irrespective of the cell death modality, the cellular decision
to survive or die relies on the integration of signals at mitochondrial membranes that
contribute to mitochondrial membrane permeability (MMP) (Kroemer et al., 2007). By
monitoring kinases upstream of MMP signaling proteins, a detailed snapshot of the cell's
own interpretation of exposure can theoretically be determined, and this early signaling
may foreshadow the cell's fate long before the final steps of cell death occur.
Appropriately capturing the time course of critical signaling events that will be
predictive of cellular survival or death post-exposure is difficult. However, time-points of
significant deviation may be determined by exploiting the intricate inter-relationship
between mitochondrial-driven energy metabolism and kinase response in real-time. Most
importantly, this can be accomplished without potentially disrupting intracellular activity.
Kinase signaling is an energy demanding process, and its reliance on phosphorylation
results in the consumption of substantial amounts of available adenosine triphosphate
(ATP) (Hammerman et al., 2004). ATP-production governs ATP-consuming processes,
such as signal transduction in mammalian cells, and this production is primarily driven by
oxidative phosphorylation within mitochondria (Buttgereit and Brand, 1995; Ainscow
and Brand, 1999). Additionally, it is known that some types of cell death (e.g., apoptosis
and autophagy) require appreciable amounts of energy due to their reliance on ATPdependent processes (Yamamoto et al., 1998; Eguchi et al., 1999; Kanzawa et al., 2004),
such as activation of caspase signaling cascades (Leist et al., 1997), chromatin
condensation (Eguchi et al., 1997), and autophagic sequestration (Kondo et al., 2005).
Therefore, by monitoring energy production processes in the cell in real-time, key time
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points of significant deviation may indicate critical kinase signaling events relevant to, in
this study, cell death post-exposure.
In this paper, we focused on a three-phased approach to forecast cell death in an
in vitro system: 1) determine time-points relevant to critical signaling events, 2)
experimentally determine the phosphorylation of proteins related to cell death and/or
survival at these significant time-points, and 3) use cluster analysis to predict the 24 hour
plasma membrane degradation dose-response of cells to xenobiotic exposure. We chose
the human hepatocellular carcinoma-derived HepG2 cell line as our model in vitro
system because the liver is rich in mitochondria (Veltri et al., 1990) and this cell line is
human-derived. Additionally, hepatocellular carcinoma incidence is on the rise in the
United States with 5-year survival rates of 10% (Altekruse et al., 2009). To test this
approach, we chose xenobiotics that have activities at disparate intracellular targets in
vitro. Specifically, we exposed HepG2 cells to various doses of 4-Benzyl-2-methyl-1,2,4thiadiazolidine-3,5-dione (TDZD-8), a glycogen synthase kinase 3β (GSK-3β) substratecompetitive inhibitor (Martinez et al., 2002). As a therapeutic target, GSK3 has seen a
recent surge in interest for its multifunctional role in a variety of signaling processes, as
well as its implication in a number of diseases, such as diabetes, Alzheimer’s, bipolar
disorder, and cancer (Kim and Kimmel, 2000; Wang et al., 2006). We also exposed
HepG2 cells to various doses of 2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone (MEK
inh II), a MEK1 inhibitor (Bakare et al., 2003). MEK1 has been shown to be
constitutively active in several carcinoma cell lines, such as hepatocellular carcinoma,
contributing to cell survival (Ballif and Blenis, 2001; Mitsui et al., 2001). This makes the
MEK1-MAPK signal transduction pathway an attractive target for chemotherapies
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(Huynh et al., 2003). By using our three-phased approach, we were able to accurately
forecast the 24 hour HepG2 plasma membrane degradation dose-response from protein
phosphorylation values as early as 20 minutes post-MEK inh II exposure and 40 minutes
post-TDZD-8 exposure. The implications of this proof of principle study may have a
broad reaching impact: from the ability to forecast in vitro cytotoxicity of xenobiotic
exposures to the identification of therapeutic windows for pharmacological treatments.

2.2 Materials and Methods
2.2.1 Materials
4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8, cas 327036-89-5),
Dulbecco's modified Eagle's medium (DMEM), sodium pyruvate, D-glucose, Lglutamate, and sodium bicarbonate were obtained from Sigma Aldrich (St. Louis, MO).
2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone (MEK inh II, cas 623163-52-0) was
purchased from CalBiochem (La Jolla, CA, USA). HEPES was purchased from Fisher
Scientific (USA). Fetal bovine serum, Ethidium homodimer-1 cytotoxicity kit, ATP
determination kit (luciferase assay), and penicillin-streptomycin were obtained from
Invitrogen (Carlsbad, CA). HyClone phosphate buffered saline (PBS) was purchased
from Thermo Scientific (USA). Cell lines and MTT assay kits were obtained from
American Type Culture Collection (Manassas, VA). MitoXpress oxygen probe was
obtained from Luxcel Corporation (Cork, Ireland). Deionized water used in this study
was prepared with the Milli-Q Water System (Millipore, Bedford, MA).
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2.2.2 Cell culture
Human hepatocellular carcinoma-derived HepG2 cells were cultured in DMEM,
supplemented with 2 g/L D-glucose, 2 mM L-Glutamate, 5 mM HEPES, 24 mM sodium
bicarbonate, 1 mM sodium pyruvate, 10% fetal bovine serum, 100 U/mL penicillin, and
100 mg/mL streptomycin. Cells were maintained in a humidified atmosphere at 37°C, 5%
CO2 and passaged at 80 % confluence.

2.2.3 Dosimetry
For MTT, NADH, cellular ATP, and plasma membrane degradation assays, cells
were seeded into clear-bottom, 96-well plates (black-sided for fluorescence assays) at a
concentration of 4 x 104 cells per well in DMEM without phenol red and allowed to grow
for 24 hours before dosing. For multiplex phosphoprotein assays, cells were seeded in 12well plates at a concentration of 5 x 105 cells per well in DMEM without phenol red and
allowed to grow for 24 hours before dosing. For oxygen consumption assays, cells were
seeded into clear-bottom, black-sided 96-well plates at a concentration of 8 x 104 cells
per well in DMEM without phenol red and allowed to grow for 24 hours before dosing.
Medium was then aspirated from wells and cells were challenged with TDZD-8 or MEK
inh II. TDZD-8 and MEK inh II were prepared so that resulting well concentrations
would be < 1 % DMSO.
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2.2.4 MTT assay
After 24 hours of exposure to TDZD-8 (10, 20, 30, 40, 50, or 100 µM) or MEK
inh II (1, 5, 10, 20, 50, or 100 µM), cell viability was determined using the MTT (3-(4,5dimethyl)-2,5-diphenyl tetrazolium bromide) assay, according to the manufacturer’s
protocol. This assay is based on the reduction of tetrazolium MTT to formazan by
metabolically active cells, in part by the action of dehydrogenase enzymes, to generate
reducing equivalents such as NADH and NADPH. Briefly, MTT reagent was added to
the wells of the microplate, and after four hours of incubation at 37°C, intracellular
formazan crystals were solubilized with the provided detergent solution. Absorbance
values were obtained using the Tecan InfiniteM1000 plate reader (Tecan US, Raleigh,
NC) with a measurement wavelength of 570 nm and a reference wavelength of 700 nm,
read from the bottom. Assay was performed in quadruplicate. Relative viability was
calculated by subtracting the negative control (contained no cells) and normalizing to
controls, which received dosing vehicle (< 1% DMSO).

2.2.5 Oxygen consumption assay
Immediately after dosing with TDZD-8 (10, 20, 30, 40, or 50 µM) or MEK inh II
(1, 5, 10, 20, or 50 µM), cellular oxygen consumption was assessed using the MitoXpress
probe, according to manufacturer’s protocol. Briefly, oxygen-sensitive probe was diluted
to a stock concentration of 1µM, and stock probe was diluted 1:15 in each well of a black
walled 96-well plate containing cells (8 x 104 cells/well); 100 µL of pre-warmed mineral
oil was also added to each well to block ambient oxygen from the cells. After pre-
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warming the plates at 37°C for 1 hour, cells were challenged with varying doses of
TDZD-8 or MEK inh II. Immediately following addition of TDZD-8 or MEK inh II,
oxygen consumption was determined by measuring fluorescence. Fluorescent signal was
obtained using the Infinite M1000 microplate reader (Tecan US, Raleigh NC) with
excitation wavelength of 380 nm and emission wavelength of 650 nm, reading from the
bottom every 10 minutes for 24 hours after dosing. Experiments were performed in
quadruplicate. Relative oxygen consumption was calculated by normalizing to controls,
which received dosing vehicle (< 1% DMSO).

2.2.6 NADH assay
Immediately after dosing with TDZD-8 (10, 20, 30, 40, or 50 µM) or MEK inh II
(1, 5, 10, 20, or 50 µM), NADH generation was determined by measuring absorbance.
The absorbance of NADH at wavelength 340 nm was measured every 10 minutes for 24
hours. Experiments were performed in quadruplicate. Relative NADH generation was
calculated by normalizing to controls, which received dosing vehicle (< 1% DMSO).

2.2.7 Cellular ATP assay
The boiling water method was used to extract cellular ATP from attached cells, as
described previously (Yang et al., 2002). After 40 minutes, 10 hours, or 24 hours of
exposure to TDZD-8 (10, 20, 30, 40, or 50 µM), medium was aspirated and cells were
washed twice with PBS. In the same manner, after 20 minutes, 8 hours 20 minutes, or 24
hours of exposure to MEK inh II (1, 5, 10, 20, or 50 µM), medium was aspirated and
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cells were washed twice with PBS. Cells were suspended in 100 µL/well boiling
deionized water with repeated pipetting. The cell suspension was transferred to a
microcentrifuge tube and centrifuged 12,000 g for 5 minutes at 4°C. Following
centrifugation, 10 µL of supernatant was used for the ATP luciferase assay, which was
performed according to the manufacturer's protocol. Bioluminescence was measured
using the Infinite M1000 microplate reader (Tecan US, Raleigh NC). Experiments were
performed in quadruplicate. Relative cellular ATP was determined by normalizing to
positive control, which received dosing vehicle (< 1% DMSO).

2.2.8 Multiplex phosphoprotein assay
After 40 minutes or 10 hours of exposure to TDZD-8 (10, 20, 30, 40, 50, or 100
µM), cells were washed with ice cold PBS and lysed according to manufacturer's
protocol. In the same manner, after 20 minutes or 8 hours 20 minutes of exposure to
MEK inh II (1, 5, 10, 20, 50, or 100 µM), cells were washed with ice cold PBS and lysed
according to manufacturer's protocol. Total protein concentration was determined using
the DC Protein Assay (BioRad, Hercules, CA) according to the manufacturer’s
instructions. Protein phosphorylation was determined by using the bead-based BioPlex
suspension array system (Bio-Rad, Hercules, CA) and lysates were prepared according to
the manufacturer’s protocol. Beads and detection antibodies against phosphorylated
AKT (Ser473), ERK1/2(Thr202/Tyr204, Thr185/Tyr187), GSK-3α/β (Ser21/Ser9),
HSP27 (Ser78), IκBα (Ser32/Ser36), JNK1/2 (Thr 183/Tyr185), MEK1 (Ser217/Ser221),
p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK (Thr359/Ser363) were obtained
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from Bio-Rad (Hercules, CA). Beads and detection antibodies against phosphorylated
BAD (Ser 112), CREB1 (Ser133), IGFR (Tyr1131), IRS1 (Ser636/Ser639), EGFR (Tyr),
MSK1(Ser212), p70S6K (Thr421/Ser424), AKT(Thr308), and p53(Ser46) were obtained
from EMD Millipore.

Relative phosphorylation was calculated by normalizing to

control, which received dosing vehicle (< 1% DMSO). TDZD-8 exposed phosphoprotein
experiments were performed in triplicate and MEK inh II exposed phosphoprotein
experiments were performed in duplicate.

2.2.9 Plasma membrane degradation assay
To determine plasma membrane degradation of HepG2 cells exposed to TDZD-8
or MEK inh II, the ethidium homodimer-1 (EthD-1) kinetic assay was used. Twenty-four
hours after seeding HepG2 cells (4 x 104) in a black-sided clear-bottom 96 well plate,
culture medium was removed and replaced with probe-containing culture medium (2 µM
EthD-1). Dead control wells were exposed to 70% methanol and the plate was incubated
for 30 minutes. Following the 30 minute incubation, cells were challenged with TDZD-8
(10, 20, 30, 40, 50, or 100 µM) or MEK inh II (1, 5, 10, 20, 50, or 100 µM) and read
immediately after dosing. Fluorescent signal was obtained using the Infinite M1000
microplate reader (Tecan US, Raleigh NC) with excitation wavelength of 530 nm and
emission wavelength of 645 nm, reading from the bottom every 10 minutes for 24 hours
after dosing. Experiments were performed in sextuplicate. Relative plasma membrane
degradation was determined by normalizing to dead control (received 70% methanol).
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2.2.10 Statistical Analysis
Dose-response curves for MTT assays were generated by best-fit Hill-plot
regression with varying slope of scatter plot data using Prism V5 (Graphpad Software,
San Diego, CA). Selection of time points related to critical signaling events (40 minutes
and 10 hours for TDZD-8; 20 minutes and 8 hours 20 minutes for MEK inh II) were
determined by estimating temporal bifurcation points from theoretical ATP generation
and activity using SAS JMP V12Pro (Cary, NC). Correlation analysis for theoretical
ATP generation and relative cellular ATP was determined using SAS JMP V12Pro (Cary,
NC). Two-way hierarchical cluster analyses with Ward's minimum variance were
determined by using SAS JMP V12Pro (Cary, NC). Statistical significance for plasma
membrane degradation (observed and forecasted) was determined by using a two-way
analysis of variance (ANOVA) with Bonferroni post-test. A difference of P < 0.05 was
considered statistically significant.

For viability, plasma membrane degradation

(observed and predicted), cellular ATP, and relative phosphorylation data, error bars
reflect standard error of the mean (S.E.M.).

2.2.11 Signaling Pathway Analysis
Functional pathway and network analyses were generated with

Ingenuity

Pathways Analysis (IPA) software (Ingenuity Systems) as described elsewhere (MadozGurpide et al., 2007). IPA identified pathways from the IPA Library of Canonical
Pathways that were significant to our phosphorylation data. The 19 proteins used in this
paper were considered for analysis. For this study, significance between our protein
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phosphorylation data set (TDZD-8 and MEK inh II) and the molecular and cellular
function p-score, along with associated network functions, was measured by Fisher’s
exact test. The Fisher's exact test calculates a p-value to determine the probability that
the relationship between the phosphorylated proteins in our data set and a canonical
pathway, biological function or disease could be related by chance alone. We reported the
top three biological functions associated with our datasets.

2.3 Results
2.3.1 HepG2 viability in response to TDZD-8 and MEK inh II
For this proof-of-principle study, we first determined the appropriate dosing range
for TDZD-8, a GSK-3β substrate-competitive inhibitor (IC50 = 2 µM) (Martinez et al.,
2002), and MEK inh II, a MEK1 inhibitor (IC50 = 0.38 µM) (Bakare et al., 2003).
Previously, MEK inh II has also been shown to inhibit other intracellular targets, such as
ERK1 (IC50 = 82.9 µM) and Raf1 (IC50 = 34.5 µM) (Bakare et al., 2003). To accomplish
this, we measured HepG2 viability via MTT assay in response to varying doses of
TDZD-8 and MEK inh II at 24 hours post-exposure (Figures 2.1a,b). From HepG2
viability, the best-fit Hill-plot regression with varying slope was used to determine the
EC50 of TDZD-8 (19 ± 1 µM) and MEK inh II (9 ± 1 µM).
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Figure 2.1. HepG2 viability to determine relevant TDZD-8 and MEK inh II doses. HepG2
viability dose-response curves for a) TDZD-8 and b) MEK inh II. Viability was measured by MTT
assay and is shown as relative viability. Relative viability was calculated relative to control cells,
which received dosing vehicle (< 1% DMSO), but no inhibitor. Dose-response curves were generated
using the best-fit Hill-plot regression with varying slope. The x-axis is shown as log2 to better
visualize TDZD-8 and MEK inh II dosing range. Error bars reflect ± S.E.M.

2.3.2 Estimation of ATP generation to determine critical signaling events
Monitoring relative ATP generation in response to chemical insult without
potentially disrupting sensitive intracellular activity is imperative. To this end, we have
developed an extracellular approach to determine kinase signaling events on a temporal
scale by estimating ATP production with data collected from real-time oxygen
consumption and NADH production assays. These data sets allow for stoichiometric
determinations of ATP production in real-time. Theoretically, mitochondrial oxidative
phosphorylation is responsible for producing a substantial portion of cellular ATP, and
traditionally, NADH and oxygen are related to ATP production as shown below
(Kadenbach, 1986; Nelson and Cox, 2008):

1
1 NADH  O2  3 ATP (1)
2
Since our assay monitors oxygen consumption, the equation can be doubled:
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2 NADH  O2  6 ATP (2)

Additionally, cells can produce ATP via glycolysis, where 1 ATP is generated for each
available NADH. This may be particularly true for HepG2 cells, since many cancer cells
have been shown to have a high reliance on glycolysis due to the Warburg effect
(Warburg, 1956; Vander Heiden et al., 2009). To account for ATP production when there
is limited or no oxygen, an “if then else loop” was used to calculate theoretical ATP
generation:

If 6  {O2 }sample  2  {NADH }sample  0;
Then
Else

[6  {O2 }sample ]  [2  {NADH }sample ]
4
{NADH }sample
4

To account for variations in ATP generation over time, we calculated the relative ATP
generation activity (equation 3), which we believe more accurately captures temporal
bifurcations relevant to critical signaling events. This equation is the average of the
integrated NADH and O2 consumption assays over time divided by their total NADH
produced and O2 consumed. We also subtracted the positive control and then added a
value of one to make generation activity curves relative to control, where a value of 1 on
the generation activity graph is the same as control.
 {NADH } sample t
 {O2 }sample t



 {NADH }sample  {O2 }sample
Relative ATP Generation Activity  
2





  {NADH }control t
 {O2 }control t
 

 
{NADH }control  {O2 }control
 
2
 
 
 
 




  1 (3)
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Bifurcation points relevant to critical signaling events are shown in figure 2.2a for
TDZD-8 (40 minutes and 10 hours) and figure 2.2b for MEK inh II (20 minutes and 8
hours 20 minutes). Bifurcations were selected by relying on the relative ATP generation
activity curves, then relating ATP generation activity curve changes to simultaneous
changes in theoretical ATP generation. The first bifurcation is the point before a
sustained increase/decrease in ATP generation activity that is simultaneously related to a
change in theoretical ATP generation curves for 3 or more doses. The second bifurcation
is selected just after there is a rapid decrease/increase in ATP generation activity that is
simultaneously related to a change in theoretical ATP generation curves for 3 or more
doses. To validate our ATP estimation method, we determined cellular ATP at the
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Figure 2.2. Theoretical ATP generation and activity models indicate key bifurcation points for
HepG2 cells exposed to TDZD-8 and MEK inh II. a) Using the NADH/NADPH absorbance at 340 nm,
NADH generation was measured every 10 minutes for 24 hours following administration of 10, 20, 30, 40,
and 50 µM doses of TDZD-8 to HepG2 cells. Data is reported as relative NADH generation, which was
normalized to controls that received vehicle control (< 1% DMSO). Oxygen consumption of HepG2 cells
exposed to TDZD-8 was monitored every 10 minutes for 24 hours with an oxygen sensitive probe
(MitoXpress). An increase in probe signal indicates an increase in oxygen consumption relative to controls,
which received dosing vehicle (< 1% DMSO). Theoretical ATP Generation (3rd graph) was calculated
using the “If then else loop”, as described in Results, which is based on the stoichiometric production of
ATP from cellular respiration (oxidative phosphorylation). Relative ATP Generation Activity (4th graph)
was calculated from Equation 3. Critical signaling events were selected at 40 min and 10 h post-TDZD-8
exposure from our bifurcation analysis described in Results. b) HepG2 cells exposed to 1, 5, 10, 20 and 50
µM doses of MEK inh II were measured and analyzed in the same way as TDZD-8. Critical signaling
events were selected at 20 min and 8 h 20 min post-MEK inh II exposure from our bifurcation analysis
described in Results. To determine if the theoretical ATP generation model predicted relative cellular ATP
levels, the luciferase assay was used to measure cellular ATP at the time-points of interest. Extracted
cellular ATP of HepG2 cells exposed to either c) TDZD-8 or d) MEK inh II were measured using the
luciferase assay as described in Materials and Methods. Relative cellular ATP from the luciferase assay of
TDZD-8 exposed cells (c) was found to be significantly correlated to our theoretical ATP generation (a, 3rd
graph) for TDZD-8 (r = 0.59, P = 0.021) at the time-points of interest (40 min, 10 h, and 24 h). Relative
cellular ATP from the luciferase assay of MEK inh II exposed cells (d) was found to be significantly
correlated to the theoretical ATP generation for MEK inh II (b, 3rd graph) for MEK inh II (r = 0.85, P <
0.001) at the time-points of interest (20 min, 8 h 20 min, and 24 h). Results were reported as relative to
controls, which received dosing vehicle (< 1% DMSO) and error bars reflect S.E.M.
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time-points of interest for each compound using the luciferase assay (Figure 2.2c,d).
Relative cellular ATP from the luciferase assay was found to be significantly correlated
to our theoretical ATP generation model for TDZD-8 (r = 0.59, P = 0.021) (Figure 2.2a,
3rd graph) and MEK inh II (r = 0.85, P < 0.001) (Figure 2.2b, 3rd graph).

2.3.3 Multiplex assay to determine phosphorylation of key proteins
After time points of critical signaling events have been identified, a snapshot of
the pharmacodynamic response to xenobiotic exposure can be determined with a highthroughput approach. Inclusion of valuable proteins that cast a wide net on cell death or
survival pathways at these time-points are necessary to capture intracellular processes
that will determine the cell's eventual fate.
xenobiotics,

endogenous

molecules),

many

In response to cellular stressors (e.g.,
kinase

pathways

converge

upon

mitochondria, which can result in mitochondrial membrane permeabilization (MMP)
mediated death (Kroemer et al., 2007; Rehm et al., 2009). From this, we chose to narrow
the list of potential proteins to those that are only a few kinase steps removed from key
survival or death proteins that are known to alter mitochondrial activity. Specifically,
mitogen-activated protein kinases (MAPKs) have been the subject of intense research for
many disease pathologies, especially cancer, due to their role in cell proliferation (Anjum
and Blenis, 2008). The EGFR-Ras-Raf-MEK-ERK-RSK signaling network is involved
in cellular proliferation, survival, differentiation, and motility (Roberts and Der, 2007);
alterations in the normal function of these proteins has been implicated in cancer and
other diseases (Sebolt-Leopold and Herrera, 2004).

Dysregulated cAMP response
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element binding protein (CREB1) has also been implicated in uncontrolled growth and
survival in several cancer cell lines, making it an excellent candidate for this approach
(Shukla et al., 2009). JNK and p38 kinases are involved in the coordinated response to
external stress stimuli, inflammation and apoptosis (for review, see Pearson et al., 2001),
making them viable candidates for this work. Another class of proteins relevant to cell
survival and death pathways are heat shock proteins (HSP), specifically HSP27, which
has been shown to act as a protective protein, binding to cytochrome c, preventing
apoptosis (Bruey et al., 2000). Two proteins intimately involved in mediating stress
stimuli signals and cell death are tumor suppressor protein p53 and Akt (Gottlieb et al.,
2002). p53-dependent apoptosis plays a critical role regulating pro- and anti-apoptotic
factors for transcription, as well as translocating from the cytosol to mitochondria, where
it interacts with proteins related to MMP (Sorrentino et al., 2013). Akt on the other hand,
has been shown to phosphorylate BCL-2 family proteins, therefore inhibiting MMP
(Datta et al., 1997). BAD, another valuable pro-apoptotic BCL-2 family protein, is an
excellent candidate protein to monitor for this approach due to its intimate relationship
with MMP-related proteins (Zha et al., 1996). To this end, a multiplex bead-based ELISA
assay was designed and used to simultaneously determine 19 different protein
phosphorylation responses for TDZD-8 and 18 different protein phosphorylation
responses for MEK inh II at time points relevant to critical signaling events from ATP
production bifurcation points. Cells were lysed at the pre-selected critical signaling time
points: 40 minutes and 10 hours post-exposure to TDZD-8 (Figure 2.3) and at 20 minutes
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Figure 2.3. Protein phosphorylation responses of HepG2 cells to TDZD-8. From the previously
determined temporal bifurcations (40 minutes and 10 hours), relative protein phosphorylation was
determined by dosing HepG2 cells with various doses of TDZD-8 (10, 20, 30, 40, 50, and 100 µM)
and lysing the cell membrane at a-b) 40 minutes and c-d) 10 hours post-exposure. Relative
phosphorylation was calculated by normalizing to controls, which received vehicle control (< 1%
DMSO). Error bars reflect S.E.M.

Figure 2.4. Protein phosphorylation responses of HepG2 cells to MEK inh II. From the
previously determined temporal bifurcations (20 minutes and 8 hours 20 minutes), relative protein
phosphorylation was determined by dosing HepG2 cells with various doses of MEK inh II (1, 5, 10,
20, 50, and 100 µM) and lysing the cell membrane at a-b) 20 minutes and c-d) 8 hours 20 minutes
post-exposure. Relative phosphorylation was calculated by normalizing to controls, which received
vehicle control (< 1% DMSO). Error bars reflect S.E.M.
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and 8 hours 20 minutes post-exposure to MEK inh II (Figure 2.4); the phosphoprotein
responses of 19 (or 18) different proteins were determined relative to control, which
received dosing vehicle (< 1% DMSO).

2.3.4 Hierarchical cluster analysis
In order to group protein responses that are relevant to varying doses of TDZD-8
and MEK inh II, we used the unsupervised (i.e., we did not pre-select clusters) Ward twoway Hierarchical clustering method (Ward, 1963) (Figure 2.5a-d). Two-way clustering is
necessary to obtain clusters of protein responses across all doses in the first dimension,
and dose clusters in the second dimension. Negative control-subtracted raw fluorescence
values for cells exposed to TDZD-8 (10, 20, 30, 40, 50, or 100 µM) or MEK inh II (1, 5,
10, 20, 50, or 100 µM), as well as cells exposed to vehicle control only (0 µM), were
used to determine cluster distances. By including the 0 µM phosphoprotein response
values, we can include the distance between no dose and the lowest experimentally
determined dose to forecast the full plasma membrane degradation dose-response.
Additionally, if we assume that an arbitrary/infinite dose of a xenobiotic (i.e., TDZD-8 or
MEK inh II) successfully kills all cells exposed, the fluorescence values due to protein
phosphorylation should theoretically be zero (via endogenous protein degradation after
the plasma membrane is compromised). From this basic theoretical assumption, we
included an "infinite dose" column with raw fluorescence values of zero for each protein
in the two-way hierarchical cluster analysis. Importantly, the inclusion of a true 0 µM
dose and a theoretical infinite dose allows for a full dose-response prediction to be made
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without experimentally testing the entire dosing range. As a visual aid, this unsupervised
hierarchical clustering method yields a heat map of phosphoprotein responses, where blue
represents low response values and red represents high response values. These clusters
are based on similarities in phosphoprotein response magnitude profiles. After
performing two-way hierarchical cluster analysis on each protein for each set of
replicates (clusters not shown, only averaged responses are depicted in Figures 2.5a-d),
cluster distances between doses were used for dose-response predictions.

2.3.5 Forecasting dose-response from hierarchical cluster analysis
By monitoring the phosphorylation response of proteins involved in cellular
survival and/or death pathways at early time-points, the fate of the cell may be forecasted.
After determining the cluster distances from two-way hierarchical cluster analysis with
Ward's minimum variance, these values were used to forecast the relative plasma
membrane degradation dose-response of TDZD-8 (Figures 2.5 e,f) and MEK inh II
exposed HepG2 cells (Figures 2.5 g,h).

To forecast the dose-response, the cluster

distance between doses including 0 µM (vehicle control) and the theoretical infinite dose
were organized in order of increasing dose. These values were then integrated across
each dose (x) interval and divided by the sum of all dose cluster distances, as described
by equation 4:

 {cluster dista nce} x
 {cluster dista nce}
i nf dose
0

(4)
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Figure 2.5. Forecasting plasma membrane degradation from two-way hierarchical cluster analysis
distances. The phosphoprotein fluorescence responses of HepG2 cells to various doses of TDZD-8 (10, 20,
30, 40, 50, and 100 µM) or MEK inh II (1, 5, 10, 20, 50, and 100 µM) were analyzed with the unsupervised
Ward two-way hierarchical clustering method. Each set of replicates were treated as a different cluster for
our analyses; however, to save space, we will show the averaged fluorescence values at each time point.
Shown above, cluster analyss of phosphoprotein responses to: a) TDZD-8 at 20 minutes post-exposure, b)
TDZD-8 at 10 hours post-exposure, c) MEK inh II at 20 minutes post-exposure, and d) MEK inh II at 8
hours 20 minutes post-exposure. After the cluster analyses were performed, the cluster distances associated
with each dose are assembled and integrated across the dosing range to formulate the forecasted relative
plasma membrane degradation dose-response curve (e-h). E) Experimentally observed relative plasma
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membrane responses to TDZD-8 at 40 minutes and 24 hours post-exposure are connected with red and
black solid lines, respectively. The forecasted 24 hour plasma membrane degradation responses that were
calculated with cluster distances from 40 minutes post-TDZD-8 exposure phosphoprotein responses are
connected with a red dashed line. F) Experimentally observed relative plasma membrane degradation
responses to TDZD-8 at 10 hours and 24 hours post-exposure are connected with blue and black solid lines,
respectively. The forecasted 24 hour plasma membrane degradation responses that were calculated with
cluster distances from 10 hours post-TDZD-8 exposure phosphoprotein responses are connected with a blue
dashed line. G) Experimentally observed relative plasma membrane degradation responses to MEK inh II at
20 minutes and 24 hours post-exposure are connected with red and black solid lines, respectively. The
forecasted 24 hour plasma membrane degradation responses that were calculated with cluster distances from
20 minutes post-MEK inh II exposure phosphoprotein responses are connected with a red dashed line. H)
Experimentally observed relative plasma membrane degradation responses to MEK inh II at 8 hours 20
minutes and 24 hours post-exposure are connected with blue and black solid lines, respectively. The
forecasted 24 hour plasma membrane degradation responses that were calculated with cluster distances from
8 hours 20 minutes post-exposure phosphoprotein responses are connected with a blue dashed line. For
graphs in figures e-h, relative plasma membrane responses were analyzed using two-way ANOVA. Clusterforecasted responses found to be significantly different (P < 0.05) from observed 24 hour responses are
marked with ^, cluster-forecasted responses found to be significantly different (P < 0.05) from early timepoint observed responses are marked with #, and observed early time-point responses found to be
significantly different (P < 0.05) from observed 24 hour responses are marked with *. Error bars reflect ±
S.E.M.

To determine if the forecasted dose-response (from early time points to TDZD-8 or MEK
inh II exposure) matched the observed 24 hour plasma membrane dose response, a twoway ANOVA was performed. The 24 hour observed and forecasted (from 40 minutes
post-TDZD-8 exposure and 20 minutes and 8 hours 20 minutes post-MEK inh II
exposure) plasma membrane responses were not significantly different at any dose. The
24 hour observed and forecasted plasma membrane degradation at 10 hours post-TDZD-8
exposure were only statistically different at the 10 µM TDZD-8 dose (P < 0.05).
Additionally, observed vs. forecasted plasma membrane degradation at the early time
points (20 minutes plasma membrane degradation post-MEK inh II exposure observed vs.
forecasted and 40 minutes plasma membrane degradation post-TDZD-8 exposure
observed vs. forecasted) were significantly different (P < 0.05) from each other at 30, 40,
50 and 100 µM TDZD-8 and 10, 20, 50, and 100 µM MEK inh II indicating that we are
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not measuring plasma membrane degradation at those early time points, rather we are
capturing early critical signaling events related to the eventual cellular fate.

2.4 Discussion
Understanding the cell's own pharmacodynamic interpretation of exposure to a
potentially toxic xenobiotic or therapeutic is imperative to determining the eventual
cellular fate. Before morphological changes (e.g., plasma membrane degradation)
indicate the overall cellular state, the intracellular domain is coordinating a dynamic and
networked response that dictates the eventual cellular outcome. By exploiting critical
pharmacodynamic events related to the eventual cellular fate decision, the cellular
response to external stimuli (e.g., xenobiotic exposure or general stress) can be forecasted
from significantly early time points post-exposure. In this paper, human hepatocellular
carcinoma derived HepG2 cells were exposed to two disparate inhibitors, TDZD-8 (GSK3β substrate-competitive inhibitor) and MEK inh II (MEK1 inhibitor), to test an approach
that combines several datasets to forecast the eventual cellular outcome. The datasets
used in this work incorporated theoretical ATP generation for the identification of critical
signaling bifurcation points, followed by determinations of the phosphoprotein response
at these time-points post-exposure for further cluster analyses to forecast the plasma
membrane degradation dose-response at 24 hours of exposure. This concept has a
universal approach: utilizing the cell's own early responses post-exposure to forecast the
cell's eventual fate that may be irrespective of the xenobiotic's intracellular mode(s) of
action.
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To our knowledge, reliable in vitro approaches that are capable of determining
important intracellular processes in real-time, such as ATP production, without
perturbing native intracellular biochemical processes have yet to be determined (Imamura
et al., 2009). Real-time oxygen consumption has been used to identify temporal events
post-xenobiotic exposure that are related to intracellular signaling, due to the relationship
between oxygen consumption and oxidative phosphorylation (Janssen-Heininger et al.,
2008). While we have had some success using oxygen consumption alone to select
critical signaling events (Boyd et al., 2013), this method can be improved by exploiting
the intricate intracellular relationship between NADH generation, oxygen consumption,
and ATP production. By extracellularly monitoring analogs of ATP production over time
after xenobiotic exposure, critical signaling events may be estimated without potentially
disrupting intracellular activity. In this manner, two bifurcation time points were
identified for HepG2 cells post-TDZD-8 or MEK inh II exposure. Since kinase signaling,
which utilizes appreciable amounts of available ATP, is an energy demanding process
(Hammerman et al., 2004), these early bifurcation points may be indicative of critical
signaling processes relevant to intracellular-level decision making for the cell's overall
eventual fate. This approach assumes that all oxygen consumption and NADH generation
measured in vitro is attributed to oxidative phosphorylation for ATP synthesis. Thus, this
model does not incorporate oxidative phosphorylation-independent oxygen consumption,
which can vary based on cell type (Herst and Berridge, 2007; Trimarchi et al., 2000).
Additionally, cellular glucose, calcium, and magnesium were not measured in this study.
For future model development, these critical cellular components may be measured to
more accurately select key time-points. This new approach may translate well into other
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cell lines with similar amounts of mitochondria, such as heart and kidney (Veltri et al.,
1990), or similar mitochondrial bioenergetics, such as the heart, testes, and brain
(Menzies and Gold, 1971). To fully validate this method, additional cell lines, both
immortalized and primary, in various tissues need to be tested.
Cell death can take a number of routes, such as necrosis, apoptosis, or autophagy,
to name a few (for review, see Galluzzi et al., 2012), whose time course after initial
exposure can last anywhere from minutes to days (Lemasters et al., 1998). Irrespective of
the cell death modality, the switch between cell death and survival revolves around the
integration of signals at mitochondrial membranes that contribute to mitochondrial
membrane permeability (MMP) (Kroemer et al., 2007). Since MMP is a major player in
the eventual cellular fate decision of survival or death, monitoring protein signaling
cascades that converge upon mitochondrial membranes is an advantageous approach.
Forecasting a cell's eventual fate can be accomplished by monitoring the phosphorylation
status of proteins that are relevant to survival and death pathways at critical signaling
time-points following exposure to xenobiotics. While the minimum number of proteins
necessary to forecast future cell death has yet to be determined, our proof of principle
study included 19 judiciously selected phosphoproteins in a multiplexable and highthroughput bead-based ELISA assay. In this work, we chose to cast a wide net on cell
death and survival pathways at pre-selected time-points to capture critical processes
responsible for determining the cell's eventual fate. The proteins selected for this study
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Figure 2.6. Ingenuity pathway analysis of phosphoprotein responses. The most significant network
interactions from the 19 different phosphoproteins measured and important intermediate proteins were
compiled in IPA. Since the proteins included in the analyses did not change for all doses at both time
points, only one dataset per inhibitor is shown in the figure. As examples, a) 50 µM MEK inh II at 20
minutes post-exposure and b) 50 µM TDZD-8 at 40 minutes post-exposure are included in the figure
above. Normalized phosphoproteins that were greater than control are shown in red and
phosphoproteins that were less than control are shown in green. IPA analysis indicated that the most
significant molecular and cellular function of both inhibitor datasets were cell death and survival;
specifically, apoptosis, cell survival, and necrosis were the most significant biological functions of the
proteins included in the analyses.

69
were confirmed to be most relevant to cell death (specifically apoptosis and necrosis) and
survival by using Ingenuity Pathway Analysis (IPA)-constructed multidirectional
interaction networks with biological function overlay (Figure 2.6a and b) to visualize the
connectivity of the proteins and their association with various biological functions. For
future development of this approach, additional phosphoproteins or different
combinations of phosphoproteins should be measured to determine the optimal number
and type of protein to forecast eventual cellular fate. Additionally, this approach only
monitored phosphoprotein responses to xenobiotic exposure. However, different types of
post-translational modifications, such as glycosylation, methylation, or acetylation, may
also be useful for this type of methodology.
While relative phosphoprotein responses of HepG2 cells to various doses of
inhibitors at key time points post-exposure offer a wealth of information about these
critical signaling events, a more digestible data platform and data transformation are
required to construct the forecasted dose-response to TDZD-8 and MEK inh II exposure.
Hierarchical cluster analysis using Ward's method produces clusters that minimize the
variance within each cluster (Ward, 1963). Going a step further, two-way cluster analysis
allows for the simultaneous clustering of both variables in this paper (i.e., phosphoprotein
response profiles and dose). In the first dimension, the protein responses across all doses
(0 µM - 100 µM and theoretical infinite dose) are clustered to minimize the within-cluster
variance and simultaneously in the second dimension, doses with similar phosphoprotein
response profiles are clustered together. It is the latter dimension that provides useful
distances based on the within-group minimized ANOVA sum of squares across all
clusters. By including the vehicle control phosphoprotein responses (0 µM) and
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theoretical infinite dose phosphoprotein responses, the forecasted dose-response range
can be computed, regardless of the actual full dose-response curve (i.e., this circumvents
the need to pre-determine exposure doses that go from 0 % cell death to 100 % cell
death). Each replicate dose cluster's ANOVA sum of squares distances were placed in
order of increasing dose (0 µM - theoretical infinite dose) and integrated across the
dosing range to formulate the forecasted relative plasma membrane degradation doseresponse curve. While this method does not pinpoint the full intracellular mode(s) of
action for the two inhibitors included in this study, the 24 hour relative plasma membrane
degradation dose-response was accurately forecasted as early as 20 minutes postexposure to MEK inh II and 40 minutes post-exposure to TDZD-8 exposure.
Additionally, the observed relative plasma membrane degradation at 20 minutes postexposure to MEK inh II and 40 minutes post-exposure to TDZD-8 has little to no death
occurring. Therefore, the phosphoprotein responses at 20 minutes and 40 minutes postexposure are likely associated with the cell's own pharmacodynamic interpretation of
exposure and eventual cell fate decision, as opposed to actual cell death occurring at this
time point.
In conclusion, this approach offers several advantages over current methodologies
to determine future xenobiotic toxicity: using extracellular techniques that do not disrupt
the native intracellular biochemical processes to estimate ATP production relevant to
critical signaling events, selecting phosphoproteins relevant to survival and/or death
pathways at critical signaling time-points that may be predictive of the cell's eventual fate
(i.e., 24 hours post-exposure), and using hierarchical cluster analysis to predict the 24
hour relative plasma membrane degradation from early phosphoprotein responses. This

71
method has been shown to accurately forecast the eventual cellular fate of HepG2 cells
exposed to two different xenobiotics, with disparate intracellular modes of action, and
may theoretically work for any intracellular mode of toxicity or cell death modality.
Finally, our results for this approach suggest that an analysis aggregating several different
protein networks may be more informative of in vitro toxicity than any individual
pathways or biomarkers. This has broad implications for many scientific fields, including
toxicology and pharmacology. These advantages allow for future studies in a highthroughput framework to quickly assess and forecast the eventual xenobiotic toxicity of
cells in vitro. Additionally, the ability to identify early critical signaling events postexposure that are related to important cellular endpoints, such as survival or death, may
significantly impact the pharmacological understanding of the therapeutic window for
treatment strategies, and potentially alter the forecasted cellular fate by probing the
endogenous signaling responses to treatments at these time points.
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Chapter 3
Forecasting cell death dose-response to mixtures in vitro
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3. Forecasting cell death dose-response to mixtures in vitro1
Individuals are continuously exposed to complex chemical mixtures, whether they
are derived from environmental or pharmaceutical (polypharmacy) exposures. While this
is an everyday reality, most chemical risk assessments are carried out on a single
chemical, or single-dose binary mixtures. Understanding and ultimately predicting
chemical mixture effects could not only elucidate potential risk factors associated with
exposures, but also offer the opportunity to develop a greater understanding of cellular
mechanisms of environmental exposure and even drug discovery. Previously, we have
shown that post-translational phosphorylation responses to chemical mixture exposures
can be predicted in vitro using Bliss Independence (Boyd et al., 2013). We have also
shown that 24 h in vitro cell death dose-response can be forecasted at significantly earlier
time-points (as early as 20 min or 40 min, depending upon the exposure) by using twoway cluster analysis of phosphorylation responses (Vrana et al., 2014). However, if both
methodologies are combined, it may be possible to forecast 24 h mixture cytotoxicity
without measuring the mixture itself;

ultimately representing a model capable of

predicting mixture toxicity using only individual compound phosphoprotein responses of
key kinases at critical signaling events. To this end, we have combined the two
methodologies to potentially forecast mixture cell death dose-response using Bliss
Independence-predicted phosphorylation values and compared those results to observedforecasted and observed values. To fully test this method, we used two different
mixtures: Deguelin and KCN (both ETC inhibitors) and MEK inh II and TDZD-8

1

Parts of this chapter have been published previously from Boyd, J., Vrana, J.A., Williams, H.N. (2013) In
vitro approach to predict post-translational phosphorylation response to mixtures. Toxicology 313, 113-21.
Reproduced with permission from Elsevier.
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(disparate kinase inhibitors). The phosphoprotein targets used in this study are key
kinases involved in cellular survival and/or death pathways. By monitoring the response
of these phosphoproteins at critical signaling time-points, the eventual cellular fate may
be forecasted. Additionally, by using Bliss Independence-predicted phosphoprotein
responses for two-way cluster analyses, cytotoxicity in response to a potential mixture
may be forecasted without experimentally measuring the mixture.

3.1 Introduction
Humans are continuously exposed to complex chemical mixtures, from the air we
breathe and the water we drink to the medications we take daily. While this is an
everyday reality, most chemical risk assessments are carried out on a single chemical, or
single-dose binary mixtures (Cedergreen et al., 2008). Traditional risk assessment testing
techniques involve screening potential agents with a single high dose exposure, using a
suite of in vivo animal models and apical endpoint analyses, such as neurotoxicity or
developmental toxicity, and narrowly-focused mode of action analysis, such as specific
cytotoxicity or mutagenicity assays (Dix et al., 2007). This low-throughput approach that
relies heavily on animal testing and high dose exposure analyses has created an enormous
backlog of chemicals waiting to be evaluated for potential toxicity (Bushnell et al., 2010;
Bhattacharya et al., 2011). This risk assessment crisis prompted the 2007 U.S. National
Research Council (NRC) report, Toxicity Testing in the 21st Century: A Vision and a
Strategy (NRC, 2007). In this report, the NRC proposed a paradigm shift from lowthroughput in vivo studies to new risk assessment strategies that utilizes high-throughput
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in vitro screening assays to exploit early cellular changes (such as signaling pathway
perturbations and alterations in cellular bioenergetics) to reveal mechanistic information
about adverse or adaptive effects after xenobiotic exposure (Hartung, 2009; Krewski et
al., 2010; Attene-Ramos et al., 2013). With this mechanistic information, better risk
assessment models can be constructed for single chemical and mixture exposure in
humans, greatly benefiting the public health sector.
New risk assessment approaches would include a suite of assays that cast a wide
net on early cellular changes, such as changes in cellular bioenergetics, and various
pathway perturbations, such as alterations in post-translational modifications (PTMs)
post-exposure, to fully understand the cellular response, whether that be adaptation after
exposure to a new homeostatic state, or cell death (Andersen and Krewski, 2009).
Understanding and eventually predicting chemical mixture effects could not only
elucidate potential risk factors associated with exposures, but also offers the opportunity
to estimate mixtures toxicity at various doses without measuring the actual mixture. With
this new risk assessment methodology in mind, we have shown that early pathway
perturbation responses, such as phosphorylation PTMs, to chemical mixture exposures
(electron transport chain (ETC) inhibitors as well as broad kinase inhibitors) can be
predicted in vitro using Bliss Independence (with accuracy > 77 %) (Boyd et al., 2013).
We have also shown that 24 h in vitro cell death dose-response can be forecasted at early
time points (as early as 20 min or 40 min, depending upon the exposure) by using twoway cluster analysis of phosphorylation responses at time points relevant to changes in
cellular bioenergetics and, consequently, perturbations in signal transduction (Vrana et
al., 2014). The potential combination of these two methodologies may offer a new model
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for risk assessment capable of harnessing early cellular changes post-exposure to predict
potential mixtures effects related to cytotoxicity. From this approach, dose-response
chemical mixture cytotoxic effects may be mathematically predicted without measuring
the actual mixture. The approach presented in this chapter could be used to test the tens
of thousands of chemicals currently used and predict all combinations at multiple doses
that have the potential to be synergistic. This would then allow current risk assessment to
narrow the experimental efforts to only those doses and chemicals of concern for further
in vivo testing
In this proof-of-concept study, we have combined the two methodologies to
forecast mixture cell death dose-response using Bliss Independence-predicted
phosphorylation values and compared those results to observed phosphorylation
response-forecasted cell death and observed cell death values. The inhibitors used as
chemical mixtures in this proof of concept study are two mitochondrial electron transport
chain (ETC) inhibitors, deguelin (0.01 - 100 µM) and KCN (0.01 - 100 µM), and two
disparate kinase inhibitors, 2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone, which is a
MEK1 inhibitor, commonly referred to as MEK inh II (0.5 - 20 µM doses) and the
substrate-competitive GSK-3β inhibitor, 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5dione, commonly referred to as TDZD-8 (1 - 100 µM doses). These mixtures were
chosen for their potential interaction and subsequent perturbation of mitochondrial
bioenergetics (deguelin and KCN), as well as potential intracellular signaling network
perturbations (MEK inh II and TDZD-8). The phosphoprotein targets used in this study
are kinases involved in cellular survival and/or death pathways. By monitoring the
response of these phosphoproteins at critical signaling time-points, the eventual cellular
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fate may be forecasted. Additionally, by using Bliss Independence-predicted
phosphoprotein responses for two-way cluster analyses, cell death in response to a
potential mixture may be forecasted without experimentally measuring the mixture.

3.2 Materials and Methods
3.2.1 Materials - Deguelin and KCN
Deguelin (CAS 522-17-8) and KCN (CAS 151-50-8) were obtained from Sigma
Aldrich (St. Louis, MO). RPMI-1640 containing phenol red, RPMI-1640 without phenol
red, sodium pyruvate, HEPES, L-glutamine, fetal bovine serum, and penicillinstreptomycin were obtained from Invitrogen (Carlsbad, CA). HepG2 cells were obtained
from American Type Culture Collection (Manassas, VA). BioPlex beads, lysis buffer,
and reagents necessary for determination of relative phosphorylation were obtained from
BioRad (Hercules, CA). Deionized water used in this study was prepared with the MilliQ Water System (Millipore, Bedford, MA).

3.2.2 Materials - MEK inh II and TDZD-8
The chemicals 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8, CAS
327036-89-5), Dulbecco's modified Eagle's medium (DMEM), sodium pyruvate, Dglucose, L-glutamate, and sodium bicarbonate were obtained from Sigma Aldrich (St.
Louis, MO). 2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone (MEK inh II, cas 62316352-0) was purchased from CalBiochem (La Jolla, CA, USA). HEPES was purchased
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from Fisher Scientific (USA). Fetal bovine serum, Ethidium homodimer-1 cytotoxicity
kit, ATP determination kit (luciferase assay), and penicillin-streptomycin were obtained
from Invitrogen (Carlsbad, CA). HepG2 cells were obtained from American Type
Culture Collection (Manassas, VA). Multiplex bead-based ELISA assays (beads,
reagents, and lysis buffers) were purchased from Bio-Rad (Hercules, CA) and EMD
Millipore (Billerica, MA). Deionized water used in this study was prepared with the
Milli-Q Water System (Millipore, Bedford, MA).

3.2.3 Cell culture
Human hepatocellular carcinoma-derived HepG2 cells were cultured in RPMI1640, supplemented with 1 mM sodium pyruvate, 5 mM HEPES, 2 mM L-Glutamine,
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin for deguelin
and KCN experiments. For MEK inh II and TDZD-8 experiments, HepG2 cells were
cultured in DMEM, supplemented with 2 g/L D-glucose, 2 mM L-Glutamate, 5 mM
HEPES, 24 mM sodium bicarbonate, 1 mM sodium pyruvate, 10% fetal bovine serum,
100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were maintained in a
humidified atmosphere at 37°C, 5% CO2 and passaged at 80 % confluence.

3.2.4 Dosimetry
For plasma membrane degradation assays, cells were seeded into clear-bottom,
96-well black-sided plates at a concentration of 4 x 104 cells per well in RPMI (or
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DMEM for MEK inh II/TDZD-8) without phenol red and allowed to grow for 24 h
before dosing. For deguelin and KCN multiplex phosphoprotein assays, cells were seeded
in 96-well plates at a concentration of 4 x 104 cells per well in RPMI without phenol red
and allowed to grow for 24 h before dosing. For MEK inh II and TDZD-8 multiplex
phosphoprotein assays, cells were seeded in 12-well plates at a concentration of 5 x 105
cells per well in DMEM without phenol red and allowed to grow for 24 h before dosing.
Deguelin, TDZD-8, and MEK inh II dosing solutions were prepared so that resulting well
concentrations would be < 1 % DMSO. KCN is water-soluable, therefore dosing
solutions were prepared in water.

3.2.5 Multiplex phosphoprotein assay - Deguelin and KCN mixtures
After 400 min of exposure to mixtures of deguelin (0.01 - 100 µM) and KCN
(0.01 - 100 µM), cells were washed with ice cold PBS and lysed according to
manufacturer's protocol. Total protein concentration was determined using the DC
Protein Assay (BioRad, Hercules, CA) according to the manufacturer’s instructions.
Protein phosphorylation was determined by using the bead-based BioPlex suspension
array system (Bio-Rad, Hercules, CA) and lysates were prepared according to the
manufacturer’s protocol. Beads and detection antibodies against phosphorylated ERK1/2
(Thr202/Tyr204, Thr185/Tyr187), AKT (Ser473), HSP27 (Ser78), IκBα (Ser32/Ser36),
JNK (Thr183/Tyr185), p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK
(Thr359/Ser363) were obtained from Bio-Rad (Hercules, CA). Relative phosphorylation
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was calculated by normalizing to control cells, which received dosing vehicle (<1%
DMSO). All experiments were performed in duplicate.

3.2.6 Multiplex phosphoprotein assay - MEK inh II and TDZD-8 mixtures
After 20 min or 40 min of exposure to mixtures of MEK inh II (0.5, 1, 2, 5, 10, or
20 µM) and TDZD-8 (1, 5, 10, 20, 50, or 100 µM), cells were washed with ice cold PBS
and lysed according to manufacturer's protocol. Total protein concentration was
determined using the DC Protein Assay (BioRad, Hercules, CA) according to the
manufacturer’s instructions. Protein phosphorylation was determined by using the beadbased BioPlex suspension array system (Bio-Rad, Hercules, CA) and lysates were
prepared according to the manufacturer’s protocol.

Beads and detection antibodies

against phosphorylated AKT (Ser473), ERK1/2 (Thr202/Tyr204, Thr185/Tyr187),
HSP27 (Ser78), IκBα (Ser32/Ser36), JNK1/2 (Thr 183/Tyr185), MEK1 (Ser217/Ser221),
and p38MAPK (Thr180/Tyr182) were obtained from Bio-Rad (Hercules, CA). Beads and
detection antibodies against phosphorylated BAD (Ser 112), CREB1 (Ser133), IRS1
(Ser636/Ser639), and p53(Ser46) were obtained from EMD Millipore. Relative
phosphorylation was calculated by normalizing to control cells, which received dosing
vehicle (<1% DMSO). All experiments were performed in duplicate.
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3.2.7 Plasma membrane degradation assay
To determine plasma membrane degradation of HepG2 cells exposed to mixtures
of deguelin and KCN or MEK inh II and TDZD-8, the ethidium homodimer-1 (EthD-1)
kinetic assay was used. Twenty-four hours after seeding HepG2 cells (4 x 104) in a
black-sided clear-bottom 96 well plate, culture medium was aspirated and replaced with
probe-containing culture medium (2 µM EthD-1). Dead control wells were exposed to
70% methanol and the plate was incubated for 30 min.

Following the 30 minute

incubation, cells were challenged mixtures of deguelin (0.01 - 100 µM) and KCN (0.01 100 µM) or mixtures of MEK inh II (0.5, 1, 2, 5, 10, or 20 µM) and TDZD-8 (1, 5, 10,
20, 50, or 100 µM) and read immediately after dosing. Fluorescent signal was obtained
using an Infinite M1000 microplate reader (Tecan US, Raleigh NC) with excitation
wavelength of 530 nm and emission wavelength of 645 nm, reading from the bottom
every 10 min for 24 h after dosing. Experiments were performed in duplicate. Relative
plasma membrane degradation was determined by normalizing to dead control (received
70% methanol). Vehicle control wells did not exceed 10 % death.

3.2.8 Statistical analysis
Correlation analysis for observed phosphoprotein mixture responses and Bliss
independence-predicted phosphoprotein mixture responses were determined using SAS
JMP V12Pro (Cary, NC). Two-way hierarchical cluster analyses with Ward's minimum
variance were determined by using SAS JMP V12Pro (Cary, NC). Statistical significance
for plasma membrane degradation (observed, forecasted, and Bliss-forecasted) were
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determined by using a two-way analysis of variance (ANOVA) with Bonferroni post-test.
A difference of P < 0.05 was considered statistically significant. For plasma membrane
degradation and relative phosphorylation data, error bars reflect standard error of the
mean (S.E.M.).

3.3 Results
3.3.1 Using Bliss independence (response addition) to predict relative phosphorylation
during critical signaling events
For this proof-of-concept study, we first determined the relative phosphorylation
of HepG2 cells exposed to individual chemicals of interest. Previously, we estimated a
critical signaling event for deguelin and KCN at 400 min post-exposure using HepG2
cells and relative oxygen consumption observations (Boyd et al., 2013). Since alterations
in oxygen consumption (cellular respiration) may suggest early perturbations of cellular
bioenergetics and potentially adverse effects, we chose a time point where all dosing
conditions experienced the highest degree of change. Previously, we also identified early
critical signaling events at 20 min and 40 min post-post exposure to MEK inh II and
TDZD-8, respectively, in HepG2 cells using our published method for estimating ATP
generation (Vrana et al., 2014). At the identified time points post-exposure, a snapshot of
the toxicodynamic response to deguelin and KCN or MEK inh II and TDZD-8 exposure
can be determined with a high-throughput approach. Inclusion of valuable proteins that
cast a wide net on cell death or survival pathways at this time point is necessary to
capture intracellular processes related to adverse or adaptive perturbation responses.
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After exposure to cellular stressors (e.g., xenobiotics, endogenous molecules), many
kinase pathways converge upon mitochondria, which can result in mitochondrial
membrane permeabilization (MMP) mediated death (Kroemer et al., 2007; Rehm et al.,
2009). From this, we chose to narrow the list of potential proteins to those that are only a
few kinase steps removed from key survival or death proteins that are known to alter
mitochondrial activity. To this end, a multiplex bead-based ELISA assay was designed
and used to simultaneously determine different protein phosphorylation responses for
deguelin and KCN (Figure 3.1) and MEK inh II and TDZD-8 (Figures 3.2) at time points
relevant to their respective critical signaling events. Cells were lysed and measured for
phosphoprotein response at the pre-selected critical signaling time points: 400 min postexposure to deguelin and KCN alone (Figure 3.1) or as a chemical mixture (Appendix

Figure 3.1. Relative phosphorylation responses of HepG2 cells exposed to deguelin or KCN.
Relative protein phosphorylation was determined by dosing HepG2 cells with various doses of deguelin
(0.01 - 100 µM) or KCN (0.01 - 100 µM) and lysing the cell membrane at 400 min post-exposure.
Relative phosphorylation was calculated by normalizing to vehicle controls. Error bars reflect S.E.M.
Assay was performed in duplicate.

3.1) and 20 min and 40 min post-exposure to MEK inh II and TDZD-8 alone (Figure 2.3)
or as a chemical mixture (Appendix 3.2-3.3). Phosphoprotein responses were determined
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relative to control, which received dosing vehicle (< 1% DMSO for deguelin, MEK inh
II, and TDZD-8, or water for KCN).

Figure 3.2. Relative phosphorylation responses of HepG2 cells exposed to MEK inh II or TDZD-8.
Relative protein phosphorylation was determined by dosing HepG2 cells with various doses of MEK inh
II (0.5, 1, 2, 5, 10, 20 µM; left graphs) or TDZD-8 (1, 5, 10, 20, 50, 100 µM; right graphs) and lysing the
cell membrane at 20 min (top graphs) or 40 min (bottom graphs) post-exposure. Relative
phosphorylation was calculated by normalizing to vehicle controls. Error bars reflect S.E.M. Assay was
performed in duplicate.
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For the same mixtures and dosing
regimen,

we

also

predicted

relative

phosphorylation responses at the key time
points of interest using Bliss independence
(Appendix 3.1-3.3), as previously shown in
Boyd,

et

al.,

2013.

Experimentally

determined phosphoprotein responses of
Figure 3.3. Deguelin and KCN mixture
correlation. Correlation plot of observed
and
Bliss
Independence-predicted
phosphoprotein mixture responses at 400
min post-exposure. Data points represent
the mean of the mixture response. For this
mixture data set, predicted values were
strongly correlated to observed values,
r(200) = 0.904, P < .0001.

individual chemicals were used to calculate
predicted values at the time points of interest.
To determine the accuracy of our prediction
method, we used correlation analysis for
observed

and

predicted

relative

phosphorylation responses (Figures 3.3-3.5). Prediction of relative phosphoprotein
responses to deguelin and KCN mixtures at 400 min post-exposure (Figure 3.3) were

Figure 3.4. MEK inh II and TDZD-8 mixture
correlation (20 min). Correlation of observed and
Bliss
Independence-predicted
phosphoprotein
mixture responses at 20 min post-exposure. Data
points represent the mean of the mixture response.
For this mixture data set, predicted values were
moderately correlated to observed values, r(432) =
0.657, P < .0001.

Figure 3.5. MEK inh II and TDZD-8 mixture
correlation (40 min). Correlation of observed and
Bliss Independence-predicted phosphoprotein
mixture responses at 40 min post-exposure. Data
points represent the mean of the mixture response.
For this mixture data set, predicted values were
weakly correlated to observed values, r(428) =
0.311, P < .0001.
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strongly correlated to experimentally determined mixture phosphoprotein responses (r =
0.904, N = 200, P < 0.0001). Prediction of relative phosphoprotein responses to MEK inh
II and TDZD-8 mixtures at 20 min post-exposure (Figure 3.4) were moderately correlated
to experimentally determined mixture phosphoprotein responses (r = 0.657, N = 432, P <
0.0001). Prediction of relative phosphoprotein responses to MEK inh II and TDZD-8
mixtures at 40 min post-exposure (Figure 3.5) were weakly correlated to experimentally
determined mixture phosphoprotein responses (r = 0.311, N = 428, P < 0.0001). The
number of data points included in the correlation analysis of MEK inh II and TDZD-8
mixtures at 40 min were 428 instead of 432 due to 4 protein-dose combinations having
instrumental error, which in this instance, was from bead aggregation.

3.3.2 Forecasting mixtures dose-response with hierarchical cluster analysis
By monitoring or predicting the phosphorylation response of proteins involved in

Figure 3.6. Observed phosphoprotein responses
for PM degradation forecast. Cluster distances to
forecast PM degradation from observed
phosphoprotein responses to mixtures of deguelin
and KCN 400 min post-exposure were calculated
with the unsupervised Ward two-way hierarchical
clustering method. PM degradation dose-response
curves were calculated using the equation above.

Figure 3.7. Bliss independence-predicted
phosphoprotein responses for PM degradation
forecast. Cluster distances to forecast PM
degradation from predicted phosphoprotein
responses to mixtures of deguelin and KCN 400
min post-exposure were calculated with the
unsupervised
Ward
two-way
hierarchical
clustering method. PM degradation dose-response
curves were calculated using the equation above.
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cellular survival and/or death pathways at early time-points, the fate of the cell may be
forecasted. In order to accomplish this, we used our previously published method (Vrana
et al., 2014), which incorporates two-way cluster analysis with Ward's minimum variance
and a transformation of the cluster distances to yield a relative cell death dose-response
(for example data analysis, see Figures 3.6-3.7). From this data, relative plasma
membrane degradation forecasts can be determined for observed phosphoprotein
responses and Bliss independence-predicted responses, and compared to experimentally
determined

relative

plasma

membrane

degradation

(Figure

3.8-3.9).

Figure 3.8. Relative PM degradation (predicted and observed) of HepG2 cells at 400 min post-exposure to
deguelin and KCN. Relative plasma membrane (PM) degradation dose-response plots depicting the 24 h
observed, 24 h cluster forecasted PM degradation from observed phosphorylation values at 400 min postexposure, and 24 h cluster forecasted PM degradation from Bliss Independence-predicted phosphorylation values
at 400 min post-exposure. Forecasted relative PM degradation responses that are significantly different from
observed 24 h PM degradation responses are marked with * (P < .05), ** (P < .01), or *** (P < .001). Observed
relative PM degradation at 400 min post-exposure had less than 10 % toxicity for all dose combinations
measured (data not shown). Forecasted relative PM degradation responses from 400 min observed
phosphorylation responses that were statistically different from Bliss-forecasted relative PM degradation
responses from 400 min predicted phosphoprotein responses were indicated with # (P < .05). Statistical
significance was determined by using two-way ANOVA with Bonferroni post-test.
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Figure 3.9. Relative PM degradation (predicted and observed) of HepG2 cells at 20 and 40 min post-exposure
to MEK inh II and TDZD-8. Relative plasma membrane (PM) degradation dose-response plots depicting the 24 h
observed, 24 h cluster forecasted PM degradation from observed phosphorylation values at 20 min (red) and 40 min
(blue) post-exposure, and 24 h cluster forecasted PM degradation from Bliss Independence-predicted phosphorylation
values at 20 min (purple) and 40 min (green) post-exposure. Forecasted (from Bliss independence-predicted
phosphoprotein responses and observed phosphoprotein responses) relative PM degradation responses that are
significantly different from observed 24 h PM degradation responses are marked with * (P < .05), ** (P < .01), or
*** (P < .001), corresponding to their respective colors. Statistical significance was determined by using two-way
ANOVA with Bonferroni post-test.
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3.4 Discussion
Humans are continuously exposed to a large number of chemicals, such as food,
air, vitamin supplements, and pharmaceuticals, at various doses, and through a variety of
exposure routes on a daily basis (Groten et al., 2001). Understanding and ultimately
predicting the possible combined effects of a given mixture exposure is necessary for risk
assessment toxicology. The current backlog of tens of thousands of chemicals entering
the environment for which there is limited or no toxicity information has initiated a
paradigm shift in traditional toxicity testing (Wilson and Schwarzman, 2009; Judson et
al., 2010; Kavlock et al., 2012; Sipes et al., 2013). This new push towards highthroughput in vitro approach would take advantage of early cellular perturbations postexposure associated with toxicity endpoints in human cell lines and tissues to elucidate
mechanistic information regarding the mode(s) of action for a potential xenobiotic or
mixture (Attene-Ramos et al., 2013). To this end, we combined our two previous
prediction models to develop this proof-of-concept study to monitor early cellular
changes relevant to signaling perturbations post-exposure for mixtures model
development and potential toxicity predictions.
By combining these two methodologies, we hope to open the door to the
possibility of predicting cytotoxicity in response to an exposure of any chemical mixture.
For the Bliss-independence predicted phosphorylation responses, the prediction model
worked exceptionally well for deguelin and KCN mixtures as well as MEK inh II and
TDZD-8 mixtures after 20 min of exposure. However, MEK inh II and TDZD-8
predictions were weakly (albeit significantly) correlated to experimentally determined
mixture responses after 40 min of exposure. This model for early PTM toxicodynamic
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responses could greatly benefit from further development since it worked well for certain
protein-dose combinations at discrete time points but missed others, especially the MEK
inh II and TDZD-8 phosphoprotein responses 40 min post-exposure. As discussed
previously in Chapter 1, mixtures prediction models often fail when an observed mixture
acts synergistically (Meled et al., 1998; Forget et al., 1999), antagonistically (Posthuma
et al., 1997; Van Gestel and Hensbergen, 1997), or experiences dose-dependent subtle
interactions (e.g., synergy for low dose mixtures and antagonist for high dose mixtures)
(Gennings et al., 2002; Jonker et al., 2004).
In this study, we also utilized our previously developed cytotoxicity forecasting
model to potentially predict 24 h plasma membrane degradation (cell death) with early
toxicodynamic perturbations. The deguelin and KCN mixtures (both observed
phosphorylation response forecasted and Bliss-predicted phosphorylation responseforecasted) were only 30 and 40 % accurate for prediction of cytotoxicity, respectively.
However, most low dose deguelin mixtures were accurately predicted (0.01 and 0.1 µM).
It is important to note that both models for deguelin and KCN mixtures were not
significantly different from each other (only 2 of 25 dose combinations were significantly
different, P < .05), suggesting that the Bliss Independence-predicted phosphoprotein
responses could be used in lieu of actual phosphoprotein mixture responses to forecast
cytotoxicity. For MEK inh II and TDZD-8 mixtures forecasts (20 min), both observed
phosphorylation response forecasted and Bliss-predicted phosphorylation responseforecasted were 75 and 50 % accurate for prediction of cytotoxicity, respectively. Also,
for MEK inh II and TDZD-8 mixtures forecasts (40 min), both observed phosphorylation
response forecasted and Bliss-predicted phosphorylation response-forecasted were 77 and
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49 % accurate for prediction of cytotoxicity, respectively. The early cellular changes
measured (i.e., phosphorylation responses of kinases related to cell death and/or survival
pathways) at 20 min post exposure were better for predicting cytotoxicity than at 40 min
post-exposure to mixtures of MEK inh II and TDZD-8. This shows that appropriate
selection of early time points, as well as judiciously selected phosphoproteins may
improve prediction models. Most imporantly, the forecasted 24 h PM degradation using
Bliss-independence

predicted

phosphoprotein

responses

accurately

forecasted

cytotoxicity (77 % and 49 % for 20 min and 40 min data, respectively). This suggests
that cytotoxicity dose-response of mixtures can be estimated without measuring the
actual mixture. The mixture predictions for MEK inh II and TDZD-8 were much more
accurate than the deguelin and KCN mixture predictions (49 – 77 % vs 30 – 40 %). This
could be due to the inclusion of 12 phosphoproteins for MEK inh II and TDZD-8
mixtures as opposed to the 8 phosphoproteins for deguelin and KCN. Additionally, MEK
inh II and TDZD-8 mixture critical signaling time points were selected from estimated
intracellular ATP, whereas deguelin and KCN mixture critical signaling time points were
selected from oxygen consumption alone.
Possible improvements to this approach could be in the type and number of PTMs
to measure for early cellular perturbations post-exposure. Previously, our forecast model
using individual compounds was very successful by using 19 phosphoprotein responses.
However, in this study, only 8 and 12 phosphoproteins were included for mixture
predictions. Future optimization of the number and identification of proteins necessary
for accurate predictions will dramatically improve our model for cytotoxicity forecasting.
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The initial success of this proof-of-concept approach suggests that highthroughput in vitro assays incorporating a wide range of doses (low, moderate, and high)
and early cellular changes to predict individual chemical and mixtures toxicity is
exceedingly advantageous. We believe that this will greatly impact xenobiotic highthroughput mixtures risk assessment in vitro, as well as pharmaceutical adverse drug
reaction analyses.
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Appendix 3.1 - Observed relative phosphorylation of deguelin and KCN mixtures
(400 min post-exposure)
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Deguelin + 0.1 M KCN (400 min)
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Deguelin + 1 M KCN (400 min)
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Deguelin + 10 M KCN (400 min)
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Deguelin + 100 M KCN (400 min)
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Appendix 3.2 - Observed relative phosphorylation of MEK inh II and TDZD-8
mixtures (20 min post-exposure)

MEK inh II + 1 M TDZD-8 (20 min)
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MEK inh II + 5 M TDZD-8 (20 min)
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MEK inh II + 10 M TDZD-8 (20 min)
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MEK inh II + 20 M TDZD-8 (20 min)
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MEK inh II + 50 M TDZD-8 (20 min)
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MEK inh II + 100 M TDZD-8 (20 min)
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Appendix 3.3 - Observed relative phosphorylation of MEK inh II and TDZD-8
mixtures (40 min post-exposure)

MEK inh II + 1 M TDZD-8 (40 min)
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MEK inh II + 5 M TDZD-8 (40 min)
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MEK inh II + 10 M TDZD-8 (40 min)
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MEK inh II + 20 M TDZD-8 (40 min)
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MEK inh II + 50 M TDZD-8 (40 min)
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MEK inh II + 100 M TDZD-8 (40 min)
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4. Using mixtures to ameliorate undesired side-effects of deguelin1
The pharmaceutical world has greatly benefited from the well-characterized
structure-function relationships of toxins with endogenous biomolecules, such as ionchannels, receptors, and signaling molecules. Thus, therapeutics derived from toxins have
been aggressively pursued. However, the multifunctional role of various toxins may lead
to undesirable off-target effects, hindering their use as therapeutic agents. In this paper,
we suggest that previously unsuccessful toxins (due to off-target effects) may be revisited
with mixtures by utilizing the pharmacodynamic response to the potential primary
therapeutic as a starting point for finding new targets to ameliorate the unintended
responses. In this proof of principle study, the pharmacodynamic response of HepG2
cells to a potential primary therapeutic (deguelin, a plant-derived chemopreventive agent)
was monitored, and a possible secondary target (p38MAPK) was identified. As a single
agent, deguelin decreased cellular viability at higher doses ( > 10 µM), but inhibited
oxygen consumption over a wide dosing range (1.0 – 100 µM). Our results demonstrate
that inhibition of oxygen consumption is related to an increase in p38MAPK
phosphorylation, and may only be an undesired side effect of deguelin (i.e., one that does
not contribute to the decrease in HepG2 viability). We further show that deguelin’s
negative effect on oxygen consumption can be diminished while maintaining efficacy
when used as a therapeutic mixture with the judiciously selected secondary inhibitor
(SB202190, p38MAPK inhibitor). These preliminary findings suggest that an
endogenous response-directed mixtures approach, which uses a pharmacodynamic

1

Parts of this chapter have been published previously, either in part or in full, from Vrana, J.A., Boggs, N.,
Currie, H.N., Boyd, J. (2013) Amelioration of an undesired action of deguelin. Toxicon 74, 83-91.
Reproduced with permission from Elsevier.
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response to a primary therapeutic to determine a secondary target, allows previously
unsuccessful toxins to be revisited as therapeutic mixtures.

4.1 Introduction
The well-characterized structure-function relationships of toxins, such as snake
venoms and plant-derived toxins, have led to major advances in understanding normal
and disease state physiology, as well as the development of pharmacological regimens
based on the structures of various toxins (McCleary and Kini, 2012). One such example
is captopril, an angiotensin-converting enzyme inhibitor to treat hypertension that is
based on bradykinin-potentiating factor (BPF) isolated from the Brazilian pit viper
Bothrops jararaca (Ferreira, 1965). Captopril has also been used in combination with
marimastat (a matrix metalloproteinase inhibitor) and fragmin (a low molecular weight
heparin approved by the U.S. FDA) as an antiangiogenesis therapeutic mixture for
patients with advanced stage cancer (Jones et al., 2004). From the successes of captopril,
among many other therapeutics derived from toxins, natural toxin-based pharmacology
has been aggressively pursued (Koh and Kini, 2012).
Previously known for their success as insecticides and fishing poisons, plantderived rotenoids, such as deguelin, have been investigated for their potential use as
chemopreventive (designed to delay the onset of cancer) and chemotherapeutic (designed
to destroy cancer after it appears) agents (Kim et al., 2008; Aggarwal et al., 2004).
Deguelin, a natural isoflavonoid isolated from the root of Lonchocarpus utilis and
Lonchocarpus urucu (Caboni et al., 2004), inhibits NADH:ubiquinone oxidoreductase
(complex I) of the mitochondrial electron transport chain (ETC), HSP90, and AKT (Lee
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et al., 2005; Oh et al., 2007, 2008; Peng et al., 2007). As a fishing poison, rotenoids are
often used due to their inhibition of cellular respiration via inhibition of complex I of the
ETC (Neuwinger, 2004). Inhibition of respiration in cells results in tissue asphyxia and
consequently organ paralysis (Neuwinger, 2004).

As a chemopreventive agent,

rotenoids, specifically deguelin, have shown promise for a variety of cancer types (Chun
et al., 2003; Murillo et al., 2002; Peng et al., 2007; Udeani et al., 1997). Unfortunately,
when used as a chemotherapeutic, rotenoids have exhibited undesirable side effects, such
as respiratory depression and cardiotoxicity, presumably due to a decrease in cellular
oxygen consumption caused by inhibition of complex I (Lee, 2004).

Additionally,

deguelin has been shown to induce a Parkinson's disease-like syndrome in rats when
administered in high doses, which is also potentially related to activity at complex I
(Caboni et al., 2004). These undesired side effects related to complex I inhibition have
hindered deguelin’s use as a chemotherapeutic agent (Agarwal and Deep, 2008; Fang and
Casida, 1998).
While deguelin has inherent faults that diminish its legitimacy as a
chemotherapeutic agent, it may still hold promise as a potential therapeutic if combined
with another xenobiotic. In recent years, using a combinatorial/mixtures approach with
targeted kinase therapeutics has shown promise as an effective strategy (Engelman et al.,
2007; Ma et al., 2005; Namiki et al., 2006; Stommel et al., 2007; Yasui et al., 2007)
because many mechanisms for cell survival rely on intricate and sophisticated
intracellular signaling networks, making single-point inhibition impractical for treatment
(Fitzgerald et al, 2006; Toschi and Janne, 2008). The initial pharmacodynamic response
to xenobiotic insult is primarily coordinated by signal transduction networks, which
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typically follow a simple framework: the phosphorylation/dephosphorylation cycle
mediated by kinases and phosphatases (Kholodenko, 2006; Sauro and Kholodenko,
2004). Since a typical cellular response to exposure involves the integration of many
kinases into pathways for a coordinated response, this enzyme class make advantageous
targets for a mixtures approach (Cohen, 2002; Collins and Workman, 2006; Dancey and
Sausville, 2003).
There are several different strategies for determining possible mixtures therapies
for kinase targets (Jackson, 1993). One strategy involves the simultaneous inhibition of a
single target using two or more compounds, while another strategy utilizes two inhibitors
to attack two different proteins on a linear pathway (e.g. mitogen-activated protein kinase
cascade) (Fitzgerald et al., 2006). A drawback to these mixtures approaches is that prior
knowledge of the network and kinases of interest are required to select which inhibitors
to use. This paper suggests an alternative strategy: instead of selecting mixtures based on
previously known mechanisms and complex networks that may not fit the cell line or
disease of interest, the endogenous response of the cell to a primary therapeutic may be
used to select the secondary target of interest. By monitoring the endogenous response of
the network while under duress from a primary therapeutic, the cell’s alternate mode of
survival can be exposed, and a second inhibitor may be selected for a more effective
mixtures therapeutic strategy.

By utilizing the endogenous response to primary

therapeutic, undesirable effects (such as decreased oxygen consumption following
exposure to deguelin) may be targeted for amelioration. Overall, this strategy holds
promise for potentially maintaining efficacy of an initial therapeutic (deguelin) while
reducing side effects for improved patient outcome.
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In this study, we investigated the endogenous response of HepG2 cells, a human
hepatocellular carcinoma-derived cell line, to a primary therapeutic (deguelin) at varying
doses to determine a potential secondary target for a beneficial therapeutic mixture. We
selected the HepG2 cell line as our model in vitro system due to the central role that the
liver plays in xenobiotic biotransformation after exposure (Mersch-Sundermann, et al.,
2004).

Most importantly, the HepG2 cell line retains endogenous xenobiotic

metabolizing enzymes, whereas primary hepatocyte culture typically loses these vital
enzymes (Knasmuller, et al., 1998). We monitored the response of HepG2 cells to
deguelin by determining 24 hour viability and kinetically measuring oxygen consumption
over 24 hours. From this data, we found a critical shift in oxygen consumption at 400
minutes post-dose that spanned several doses. At this time-point, we monitored the
relative post-translational phosphorylation of 8 proteins involved in cell proliferation or
apoptotic signal transduction cascades. From this phosphorylation response data, we
selected p38MAPK as a secondary target, and used a specific p38MAPK inhibitor
(SB202190) in combination with deguelin to possibly alter the overall cellular response
to deguelin. We found that by using an endogenously selected therapeutic mixture,
deguelin’s inhibition of oxygen consumption was diminished while maintaining efficacy.
This proof of principle study shows that by using an endogenous response-directed
mixtures approach, previously unsuccessful toxins as a primary therapeutic may be
revisited.
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4.2 Materials and Methods
4.2.1 Materials
Deguelin (CAS no. 522-17-8) and SB202190 (CAS no. 152121-30-7) were
obtained from Sigma Aldrich (St. Louis, MO).

RPMI-1640 containing phenol red,

RPMI-1640 without phenol red, sodium pyruvate, HEPES, L-glutamine, fetal bovine
serum, and penicillin-streptomycin were obtained from Invitrogen (Carlsbad, CA). Cell
lines and MTT assay kits were obtained from American Type Culture Collection
(Manassas, VA). MitoXpress oxygen probe was obtained from Luxcel Corporation
(Cork, Ireland). BioPlex beads, lysis buffer, and reagents necessary for determination of
relative phosphorylation were obtained from BioRad (Hercules, CA).

4.2.2 Cell culture
Human hepatocellular carcinoma-derived HepG2 cells were cultured in RPMI1640, supplemented with 1 mM sodium pyruvate, 5 mM HEPES, 2 mM L-Glutamine,
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were
maintained in a humidified atmosphere at 37°C, 5% CO2 and passaged at 80 %
confluence.
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4.2.3 Dosimetry
Cells were seeded into clear-bottom, black-sided 96-well plates at a concentration
of 4 x 104 cells per well in RPMI-1640 without phenol red and allowed to grow for 24
hours before dosing. Media was then aspirated from wells and cells were challenged
with varying doses of single and mixed compounds in fresh media. Compounds were
prepared so that resulting well concentrations would be <1% DMSO and 0.01 µM to 100
µM (deguelin) and 350 nM (SB202190).

4.2.4 MTT assay
After 24 hours of exposure to single compounds or mixtures, cell viability was
determined using the MTT (3-(4,5-dimethyl)-2,5-diphenyl tetrazolium bromide) assay,
according to the manufacturer’s protocol. The assay is based on the reduction of
tetrazolium MTT to formazan by metabolically active cells, in part by the action of
dehydrogenase enzymes, to generate reducing equivalents such as NADH and NADPH.
Briefly, MTT reagent was added to the wells of the microplate, and after two hours of
incubation at 37°C, intracellular formazan crystals were solubilized with the provided
detergent solution. Absorbance values were obtained using the Safire2 microplate reader
(Tecan US, Raleigh, NC) with a measurement wavelength of 570 nm and a reference
wavelength of 700 nm, read from the bottom. Experiments were each performed at least
in triplicate. Percent viability was calculated by normalizing to controls, which received
dosing vehicle (1% DMSO).
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4.2.5 Oxygen consumption assay
Immediately after dosing with single compounds or mixtures, cellular oxygen
consumption was assessed using the MitoXpress probe, according to manufacturer’s
protocol. Briefly, oxygen-sensitive probe was diluted to a stock concentration of 1μM,
and stock probe was diluted 1:15 in each well of a 96-well plate containing cells; 100μL
of pre-warmed mineral oil was also added to each well to block ambient oxygen from the
cells. After pre-warming the plates at 37°C for 1 hour, cells were challenged with
varying doses of deguelin alone or in combination the IC50 of SB202190 (350nM).
Immediately following addition of compound(s), oxygen consumption was determined by
measuring fluorescence.

Fluorescent signal was obtained using the Infinite M1000

microplate reader (Tecan US, Raleigh NC) with excitation wavelength of 380 nm and
emission wavelength of 650 nm, reading from the bottom every 10 minutes for 24 hours
after dosing.

Experiments were performed in quadruplicate.

Relative oxygen

consumption was calculated by normalizing to controls, which received dosing vehicle
(1% DMSO).

4.2.6 Bio-Plex Multiplex Immunoassay
After 400 minutes of exposure (Boyd et al., 2012) to increasing doses of deguelin
(0.01, 0.1, 1.0, 10, 100 µM) in 1% DMSO alone, or in combination with IC50 of
SB202190 (350nM), cells were lysed using lysis buffer (BioRad, Hercules, CA) with
500µM phenylmethanesulfonylfluoride (PMSF) (Sigma, St. Louis, MO) and phosphatase
inhibitors (BioRad, Hercules, CA). Total protein concentration was determined using the
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DC Protein Assay (BioRad, Hercules, CA) according to the manufacturer’s instructions.
Protein phosphorylation was detected using multiplex bead-based BioPlex suspension
array system (Bio-Rad, Hercules, CA) and lysates were prepared according to the
manufacturer’s protocol. Beads and detection antibodies against phosphorylated ERK1/2
(Thr202/Tyr204, Thr185/Tyr187), AKT (Ser473), HSP27 (Ser78), IκBα (Ser32/Ser36),
JNK (Thr183/Tyr185), p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK
(Thr359/Ser363) were obtained from Bio-Rad (Hercules, CA). Relative phosphorylation
was calculated by normalizing to control cells, which received dosing vehicle (1%
DMSO). All experiments were performed in duplicate.

4.2.7 Statistical Analysis
Dose-response curves for MTT assays were generated by best-fit Hill-plot
regression of scatter plot data using Prism V5 (Graphpad Software, San Diego, CA).
Oxygen consumption curves were generated by choosing the best-fit polynomial
regression of scatter plot data using Prism V5 (Graphpad Software, San Diego, CA). The
time point of interest (400 min) was selected using SAS JMP V8 (Cary, NC) where the
change in the slope of the oxygen consumption curve reached a minimum for most
exposures. Statistical significance for viability and relative phosphorylation was assessed
by using a two-way analysis of variance (ANOVA) with Bonferroni post-test. Statistical
significance for oxygen consumption (a kinetic assay) was assessed by using a KruskalWallis nonparametric test with Dunns post-test. A difference at P < 0.05 level was
considered statistically significant. For viability and relative phosphorylation data, error
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bars reflect standard error of the mean.

For oxygen consumption curves (best-fit

polynomial regression), error was reported at the 95% confidence interval.

4.3 Results
4.3.1 Deguelin as a monotherapy
To determine the overall effect of deguelin alone, HepG2 cells were exposed to
log doses of deguelin (0.01 – 100 µM) and viability at 24 hours post-dose was measured
using the MTT assay (shown in Figure 4.1). Our viability data suggests that deguelin is
effective at doses greater than 10µM (EC50 = 45 ± 1 µM).

Figure 4.1. Percent viability of HepG2 cells in response to 24 hour exposure of 0.01 – 100 µM
deguelin. Viability, shown as % viability, was measured as in Methods and was calculated relative to
control cells which received dosing vehicle (<1% DMSO) only. Dose-response curve was generated
by a best-fit Hill-plot regression of scatter plot data. Error is reported as ± standard error of the mean
(SEM).
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4.3.2 HepG2 viability (in response to
deguelin)

may

not

be

associated

with

O2

To

better

relate

directly

consumption
deguelin's

inhibition of oxygen consumption to
endpoint

viability,

we

kinetically

measured the oxygen consumption of
HepG2 cells in response to deguelin
over 24 hours post-dose, as shown in
Figure 4.2, using the MitoXpress
oxygen consumption assay.
Figure

4.2,

oxygen

From

consumption

decreased when in the presence of 1.0
– 100 µM doses of deguelin (as

Figure 4.2. Percent oxygen consumption of HepG2
cells in response to 0.01 – 100 µM deguelin. Oxygen
consumption response of HepG2 cells to increasing doses
of deguelin (shown in shades of gray) measured over 24
hours.
Oxygen consumption was measured using
MitoXpress extracellular assay as outlined in section 2.5.
Percent oxygen consumption is shown relative to control
cells which received dosing vehicle (<1% DMSO) only.
Oxygen consumption curves were generated using a bestfit polynomial function with error bars reflecting the 95%
confidence intervals. Vertical line at 400 minutes was
selected as the time-point of greatest disparity in oxygen
consumption.

compared to controls, represented as percent oxygen consumption). A Kruskal-Wallis
nonparametric test with Dunns post-test was used to compare oxygen consumption
responses to various doses.

The oxygen consumption responses at all doses were

statistically different (P < 0.05) from each other except for 1.0 µM vs 10 µM and 10 µM
vs 100 µM.

Most importantly, there is a clear separation in oxygen consumption

responses between two dosing groups: the lowest doses (0.01 and 0.1 µM) and the higher
doses (1.0 – 100 µM). Since our oxygen consumption data at these doses does not seem
to correspond with our MTT assay (which demonstrated no decrease in viability for the
1.0 and 10 µM doses), the inhibition of oxygen consumption may not be directly
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associated with 24 hour HepG2 viability in response to deguelin. Furthermore, for the
lower doses of deguelin (0.01 and 0.1 µM), oxygen consumption actually increases
relative to controls until about 400 minutes post-exposure; at this time-point, oxygen
consumption decreases, ultimately returning to control levels. Therefore, 400 minutes
appears to be an interesting time point post-exposure that results in the greatest disparity
in oxygen consumption between high and low doses. Since the full dosing regimen of
deguelin indicated 400 minutes post-dose as a key time-point where doses of deguelin
lead to both decreased (1.0 – 100 µM) and increased (0.01, 0.1 µM) oxygen
consumption, we investigated the post-translational phosphorylation response to identify
the underlying signal transduction events that allow for both decreased oxygen
consumption and survival (ie. ~100% viability) at the 1.0 and 10 µM doses. This method
of selecting critical time-points of phosphorylation events from oxygen consumption data
has been previously used by Boyd et al. (2012).

4.3.3 Endogenous phosphorylation response to deguelin exposes a potential secondary
therapeutic target
We next explored the signal transduction response, by means of post-translational
phosphorylation activity, of HepG2 cells exposed to increasing doses of deguelin. We
simultaneously
Thr185/Tyr187),
(Thr183/Tyr185),

measured
AKT

the

phosphorylation

(Ser473),

p38MAPK

HSP27

of

(Ser78),

(Thr180/Tyr182),

p53

ERK1/2
IκBα

(Thr202/Tyr204,

(Ser32/Ser36),

(Ser15),

and

JNK

p90RSK

(Thr359/Ser363) at 400 minutes post-exposure to deguelin using bead-based ELISA flow
cytometry. These protein targets were selected because of their relevance in signal
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transduction pathways related to cellular death and recovery [Dong et al., 2002; Jin and
El-Deiry, 2005; Oren, 2003; Wilkinson and Millar, 2000], and due to the availability of
selective inhibitors. Figure 4.3 shows the relative phosphorylation response of HepG2
cells to 400 minute exposures of increasing doses of deguelin (as compared to controls,
normalized to a value of 1). A two-way ANOVA with Bonferroni post-test determined
significant differences (P < 0.05) between deguelin-exposed and control cells for
p38MAPK at 0.1 µM; ERK1/2, JNK, p38MAPK, IκBα, p53, and p90RSK at 1.0 µM; for
all proteins except JNK at 10 µM; and for all proteins at 100 µM (Figure 4.3). While
several proteins experienced a relative phosphorylation change in response to deguelin at
400 minutes post-dose, p38MAPK phosphorylation is statistically different across four
orders of magnitude of dose (1.0 – 100 µM).

Figure 4.3. Relative phosphorylation of protein targets in response to 0.01 – 100 µM deguelin. Posttranslational phosphorylation response of protein targets (from cell lysates) to 400 minute exposures of
deguelin as outlined in Methods; responses are shown relative to control cells, which received dosing vehicle
(<1% DMSO), but no deguelin. The solid black line at y = 1 shows where observed post-translational
phosphorylation responses are the same as control. The phosphorylation responses found to be significantly
different (P < 0.05) from controls are marked with *.
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4.3.4 Using mixtures to suppress
endogenous p38MAPK response to
deguelin
To determine if our directed
mixtures approach, which takes
advantage

of

the

pharmacodynamic
Figure 4.4. Relative p38MAPK phosphorylation in
response to deguelin, SB202190, and mixtures of
deguelin with SB202190. The phosphorylation response
of p38MAPK from cell lysates at 400 minute exposures
to mixtures of deguelin and 350 nM SB202190 (black),
deguelin alone (white), and 350 nM SB202190 alone
(black dots with grey line representing standard error of
the mean) as discussed in sections 2.6 and 3.4; all values
are reported as relative to control cells, which received
dosing vehicle (<1% DMSO) only. Error is reported as
± SEM. Post-translational phosphorylation responses of
the mixture found to be significantly different (P < 0.05)
from deguelin alone are marked with * and those
different (P < 0.05) than SB202190 alone are marked
with #.
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on

oxygen
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phosphorylation

response to deguelin by using a

secondary inhibitor, SB202190. We chose SB202190 because it is a selective inhibitor of
p38MAPK (Lee et al., 1994). HepG2 cells were exposed to SB202190 alone at its
manufacturer reported IC50 (350 nM) and in combination with a full range of deguelin
doses (0.01 – 100 µM), and we measured the p38MAPK post-translational
phosphorylation response at 400 minutes post-dose (shown in Figure 4.4). From this
figure, SB202190 alone does decrease the phosphorylation response of p38MAPK (0.61
± 0.02) when compared to controls, indicating that it is a relatively potent inhibitor (350
nM) of p38MAPK.

A two-way ANOVA with Bonferroni post-test determined

significant differences (P < 0.05) between the p38MAPK response to deguelin alone and

132

the mixture, as well as SB202190 alone and the mixture. Most notably the relative
p38MAPK phosphorylation responses to mixtures of deguelin (0.1 – 10 µM) with
SB202190 were significantly decreased in comparison to deguelin alone.

4.3.5 Mixtures approach retains efficacy while decreasing deguelin’s effect on O2
consumption
To test this new potential therapeutic regimen, we exposed HepG2 cells to
varying doses of deguelin (0.01-100 µM) in combination with SB202190 at its
manufacturer reported IC50 (350
nM) and measured viability (Figure
4.5).

At 24 hours post-dose,

viability was measured following
treatment with SB202190 alone and
in

combination

with

deguelin

(Figure 4.5), and compared to
viability data for deguelin alone
(controls measured concurrently).
SB202190

alone

did

not

significantly decrease viability at
the 350 nM dose (98 ± 3 %).
Viability was slightly decreased in
response to mixtures of deguelin

Figure 4.5. Percent viability of HepG2 cells in
response to 24 hour exposure of deguelin alone and
in combination with SB202190. HepG2 viability in
response to deguelin alone (triangles), mixtures of
deguelin and 350 nM SB202190 (circles), and 350 nM
SB202190 alone (black dotted line with grey shading
for SEM). Viability, shown as % viability, was
measured as outlined in section 2.4, and was calculated
relative to control cells which received dosing vehicle
(<1% DMSO), but no deguelin or inhibitor doses.
Dose-response curves were generated by best-fit Hillplot regression of scatter plot data. Mixture viability
responses found to be significantly different (P < 0.05)
from deguelin are marked with * and those different (P
< 0.05) from SB202190 are marked with #.
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(EC50 = 33 ± 1 µM) when compared to deguelin alone (EC50 = 45 ± 1 µM). To determine
the effect of this mixtures technique on oxygen consumption, HepG2 cells were exposed
to a full dosing regimen of deguelin (0.01 – 100 µM) in combination with SB202190
(350 nM). Immediately after dosing, oxygen consumption was measured kinetically over
24 hours and compared relative to controls, shown as percent oxygen consumption. From
Figure 4.6, SB202190 alone did not affect oxygen consumption from 0 – 600 minutes
post-dose.

Figure 4.6.
Percent
oxygen consumption of
HepG2 cells in response
to deguelin alone, and
in combination with
SB202190.
Oxygen
consumption response of
HepG2
cells
to
SB202190
alone
(squares), deguelin alone
(triangles) and deguelin
with 350 nM SB202190
(circles) measured over
24 hours.
Oxygen
consumption
was
measured
using
MitoXpress extracellular
assay as outlined in
section 2.5.
Oxygen
consumption is shown
relative to control cells,
which received dosing
vehicle (<1% DMSO),
but no deguelin or
SB202190.
Oxygen
consumption curves were
generated using a best-fit
polynomial
function
(solid
line)
with
surrounding dotted lines
reflecting
the
95%
confidence intervals.

However, after 600 minutes SB202190 decreased oxygen consumption. Mixtures of
deguelin (0.01 – 100 µM) with 350 nM SB202190 sustained oxygen consumption (100%
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oxygen consumption relative to controls) for 0.01 µM and 0.1 µM, or increased oxygen
consumption (1.0 – 100 µM), whereas exposure to deguelin alone inhibited oxygen
consumption at doses of 1.0 – 100 µM. A Kruskal-Wallis nonparametric test with Dunns
post-test was used to compare oxygen consumption responses between doses of deguelin
alone and in combination with SB202190. When compared to oxygen consumption in
response to deguelin alone, mixture doses were statistically different (P < 0.05) for 1.0,
10 and 100 µM. When considering viability, efficacy of the highest mixture dose was
sustained, while oxygen consumption at the highest mixture dose of deguelin (100 µM)
with SB202190 was significantly increased (P < 0.05) when compared to 100 µM
deguelin alone. By increasing oxygen consumption using this endogenously-directed
mixtures approach, we were able to successfully ameliorate an undesired alternative
action of deguelin.

4.4 Discussion
Due to the activity of various toxins at specific intracellular proteins, therapeutic
agents derived from these toxins have been aggressively pursued (McCleary and Kini,
2012). One such example is cobrotoxin, a protein isolated from the venom of the Taiwan
cobra Naja naja atra (Chang et al., 1997). Cobrotoxin binds to nuclear factor-κB (NFκB) signaling molecules with high affinity, such as p50 and inhibitory κB kinases (IKKs)
(Park et al., 2005). Therapeutic agents capable of suppressing NF-κB are constantly
being explored due to abnormal or constitutive NF-κB activity in many cancer types
(Dolcet et al., 2005). Cobrotoxin's inhibition of NF-κB signaling molecules suppresses
NF-κB activity, making cobrotoxin an advantageous chemotherapeutic agent (Son et al.,
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2007).

From this ideology, the present proof of principle study has demonstrated that an

endogenous response-directed mixtures approach may be useful for diminishing possible
off-target effects while maintaining efficacy of naturally-derived potential therapeutics.
Deguelin, a plant-derived chemopreventive agent, has been shown (Figure 4.1) to
decrease HepG2 viability at high doses. Previously, deguelin has been shown to alter
activity at different intracellular proteins, such as AKT and HSP90 (Lee et al., 2005; Oh
et al., 2007, 2008; Peng et al., 2007), making it a valid candidate for kinase-targeted
chemotherapy.

However, deguelin has also been shown to affect mitochondrial

bioenergetics, presumably due to its activity at complex I of the electron transport chain
(Fang and Casida, 1998;Gerhauser, et al., 1997). Previously, this inhibitory activity has
been shown to decrease intracellular oxygen consumption in a mouse skin model
(Gerhauser, et al., 1997), which may also contribute to cellular toxicity at distal cells.
Our results (Figure 4.2) indicate that off-target inhibition of oxygen consumption was
sustained over 24 hours in response to a range of doses (1.0 – 100 µM) of deguelin when
it was used as a monotherapy. While inhibition of oxygen consumption was sustained
over a wide dosing range, a significant decrease in HepG2 viability occurs only at doses
greater than 10 µM. This suggests that deguelin’s inhibition of oxygen consumption may
not be contributing to the decrease in HepG2 viability. It is known from the Warburg
Effect that cancer cells can utilize aerobic glycolysis for ATP production, whereas
differentiated cells primarily produce ATP via oxidative phosphorylation that requires
sufficient amounts of oxygen (Warburg, 1956). In the absence of oxygen, it is difficult
for differentiated cells to produce enough ATP from anaerobic glycolysis for survival,
thus many undergo apoptosis under hypoxic conditions. However, cancer cells, such as
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HepG2, can survive in an oxygen-deficient environment due to their reliance on aerobic
glycolysis to produce ATP [for a review, see Vander Heiden et al., 2009]. Therefore, the
Warburg Effect, in conjunction with our results, supports that deguelin’s activity at
separate intracellular sites may be causing decreased viability, whereas inhibition of
oxygen consumption is possibly an undesirable alternative activity of deguelin that limits
its usefulness as a possible therapeutic (Lee et al., 2005; Oh et al., 2007, 2008).
To better understand the discrepancies in HepG2 viability and oxygen
consumption in response to deguelin, we investigated the post-translational
phosphorylation response of several key proteins involved in cell recovery or proapoptotic signaling cascades (Figure 4.3). We found that p38MAPK phosphorylation in
response to deguelin is significantly different over several orders of magnitude (0.1 – 100
µM) of dose. For 0.1 – 10 µM doses of deguelin, the relative phosphorylation response
of p38MAPK is significantly increased. With regard to HepG2 viability, the 0.1 – 10 µM
dosing range is ineffective, indicating p38MAPK as a possible protein involved in an
endogenous defense mechanism that improves survival against deguelin. This is further
supported by the decrease in relative phosphorylation of p38MAPK in response to 100
µM dose of deguelin that coincides with decreased viability at this dose, indicating the
cell may not be able to effectively respond to a high dose of deguelin. This preliminary
data suggests that a directed mixtures approach utilizing p38MAPK as a secondary target,
thereby capitalizing on the endogenous response to deguelin, may be advantageous.
However, it should be noted that due to the limited number of proteins measured in this
study, there may be activity at other proteins/cascades that could be influencing the
overall pharmacodynamic response to deguelin.
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While monotherapies for cancer have proven to be successful when a single target
controls the cell’s fate, many carcinomas are often more complex, with intricate signaling
networks governing proliferation (Toschi and Janne, 2008).

This complex survival

framework, capable of facilitating uncontrolled proliferation, can withstand the inhibition
of a single target by switching to an alternate mode for survival. However, by utilizing
the endogenous response to a single insult (primary therapeutic), a second inhibitor may
be used as a mixture with the primary therapeutic for a more effective treatment.
Combinatorial approaches have previously been shown to improve various cancer
therapies (Engelman et al., 2007; Fitzgerald et al., 2006; Ma et al., 2005; Namiki et al.,
2006; Stommel et al., 2007; Toschi and Janne, 2008; Yasui et al., 2007). To this end, we
combined a selective p38MAPK inhibitor, SB202190, with deguelin to suppress the
endogenous p38MAPK response to deguelin alone (Figure 4.4). Additionally, when used
as a therapeutic mixture, efficacy of deguelin was maintained (Figure 4.5). While
SB202190 has been shown to be a selective p38MAPK inhibitor, we recognize that
inhibitors are not perfect and may alter the activity of undesired intracellular proteins
(Muniyappa and Das, 2008). Additionally, SB202190 has been shown to be toxic in a
human leukemia cell line 24 hours post-exposure at higher doses (50 μM) (Nemoto et al.,
1998). In this study, we found that SB202190 (350 nM) alone did not significantly
decrease HepG2 viability 24 hours post-exposure (Figure 4.5). It should be noted that the
diverse role of p38MAPK signaling, for example the conflicting results during
ischemia/reperfusion injury (for review, see Steenbergen, 2002), after cellular stress or
xenobiotic exposure can vary based on the model system used (Cuadrado and Nebreda.
2010).
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By using this directed mixtures approach, the undesired alternative action of
deguelin (inhibition of oxygen consumption) can be ameliorated without sacrificing
efficacy. From Figure 4.6, SB202190 treatment alone decreased oxygen consumption
slightly, but treatment with the various mixtures led to an increase in oxygen
consumption when compared to deguelin alone, thus minimizing deguelin’s undesired
effect on oxygen consumption. Most notably, the highest mixture dose showed an
increase in oxygen consumption when compared to 100 µM of deguelin alone, while
maintaining efficacy (less than 15% viability). These results are consistent with previous
studies that monitored mitochondrial bioenergetics in response to ETC inhibitors (Arvier
et al., 2007; Dumas et al., 2003; Roussel et al., 2003). Desquiret and coworkers (2008)
found that dexamethasone, a synthetic glucocorticoid, inhibits mitochondrial activity
(specifically complex I and II) in HepG2 cells. Since glucocorticoid stimulation activates
G protein-coupled receptor (GPCR), they hypothesized that GPCR mediated kinase
pathways may be key players in regulating rapid glucocorticoid activity at ETC
complexes. From this, they co-exposed HepG2 cells to dexamethasone and SB202190
(since p38MAPK is downstream of GPCR), and found that SB202190 increased
Complex I activity by 80%, when compared to HepG2 cells exposed to dexamethasone
alone, which demonstrates the vital role p38MAPK plays in mediating mitochondrial
bioenergetics after xenobiotic exposure. By using our proposed mixtures approach, the
undesired alternative action of deguelin (inhibition of oxygen consumption) was
diminished by inhibiting p38MAPK.
As a proof of principle, the novel mixtures approach presented here exploits the
endogenous intracellular response to a primary therapeutic, revealing a secondary target
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for a combinatorial therapeutic regimen. By using this endogenously selected mixture,
the cell’s native response mechanism against a primary therapeutic is inhibited, making
the intracellular signaling network less effective at cell recovery and decreasing viability.
From this directed mixtures approach, a primary therapeutic’s efficacy can be
maintained, while potentially decreasing undesired side effects. Additionally, by using
this approach, previously unsuccessful therapeutics derived from toxins can be revisited.
This ultimately speaks to the significance of pharmacodynamic mixtures that target
kinase responses as an avenue of future research.
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5. Future directions: Expanding concepts to human interaction
The work presented in this dissertation was meant to understand early cellular
changes, whether that be alterations in cellular bioenergetics or pathway perturbations,
and use the resulting mechanistic information to formulate new toxicity prediction
models. With better prediction models that harness the mechanistic information from well
planned, high-throughput in vitro experiments, many more individual chemicals and
mixtures can be properly assessed for toxicity risk assessment. The success of the
prediction models presented in this dissertation may greatly impact xenobiotic highthroughput mixtures risk assessment in vitro, as well as pharmaceutical adverse drug
reaction analyses. Additionally, this fundamental research may be expanded to human
research interaction studies, where intercommunication and team dynamics may
contribute to responses of individuals on a team (human mixtures). Preliminary research
regarding this new application is presented in this chapter.

5.1 Introduction
Perturbations of biological processes by chemical stress exposure can elicit early
cellular changes, leading to an adaptive stress response for continued survival or adverse
response leading to toxicity (Andersen, 2010). The term "stress" is not exclusive to
exogenous xenobiotics, but also extends to external stimuli that initiate endogenous stress
signaling biomolecules, such as cytokines, hormones, and catecholamines, to name a few
(Boelsterli, 2007). In light of this classification, the same high-throughput approach for
measuring xenobiotic chemical stress for individual compounds or chemical mixtures

147
may be applied to human interaction studies to understand the dynamic molecular
response to social stress and teamwork. With this approach, teams can be constructed to
reduce individual "stress," improve teamwork, and develop models incorporating human
interaction stress responses for risk assessment.
In the presence of stress-inducing stimuli, there is bimodal communication between
the brain and body, which is coordinated by the autonomic nervous system (ANS), endocrine
and immune systems (McEwen, 2005; McEwen, 2007). This bimodal communication relies
on dynamic chemical messengers released to promote adaptation (allostasis) in response to
environmental, psychological, and physiological stressors (Chida and Hamer, 2008). The
initiation of these messengers can be measured as early as seconds to minutes after an
individual perceives a situation or stimuli as a threat (Sapolsky et al., 2000). The perception
of threat and allostatic responses to external stimuli, whether they are real or imagined, can
vary depending upon individual inherent (genetic makeup or development), behavioral
(lifestyle choices and mechanisms for coping), and historical (previous trauma or major life
events) factors (McEwen, 1998; Juster et al., 2010). These components drive individual
resiliency or sensitivity to stress. Sensitivity to repeated acute stressors over time can lead to
chronic stress and disease states. The Allostatic Load (AL) model has been used over the last
two decades to better understand the physiology of stress, especially as it relates to effects of
stress in the workplace and at home (McEwen and Stellar, 1993; Ganster and Rosen, 2013).
The AL model has numerous potential applications for various fields of study to monitor
individuals and teams that are under substantial amounts of stress, whether it be medical
(doctors, nurses, paramedics), business and management (market traders, both small and
large companies), athletic teams, or military units.
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Research investigating social relationships as they relate to physical health has
been well documented (House et al., 1988; Umberson and Montez, 2010). Supportive
relationships and interactions have been shown to improve immune, endocrine, and
cardiovascular responses to stress and reduce overall AL (Cohen, 2004; Kiecolt-Glaser et
al., 2005). With this in mind, allostatic responses to a perceived threat, competition, or
risk taking may be different when a task is performed as a team rather than an individual.
In the presence of acute stress-inducing stimuli, the AL model proposes the
following mechanism for primary processes for initial adaptation to stress. Primary
processes of the AL model include psychological (fear or anxiety), physiological
(cortisol, catecholamines, cytokines), and psychosomatic (fatigue or sleep disturbance)
mediators (McEwen, 2003; Ganster and Rosen, 2013). Recent trends in AL research
suggest moving away from single biomarkers to a more inclusive and comprehensive
multiplex approach (Khan, 2012; Ganster and Rosen, 2013), casting a wide net on
multiple

physiological

pathways

(neuroendocrine,

immune,

metabolic,

and

cardiovascular) to elucidate an individual's acute and/or chronic stress response, similar
to the recent NRC report suggestions (NRC, 2007).
To this end, we initiated a human research study to monitor individual and team
physiological metrics and elucidate adaptive biomolecular responses relevant to
teamwork stress and performance. In this study, we enrolled Air Force Reserve Officers’
Training Corps (ROTC) cadets to perform a mock hostage rescue mission alone and as
part of a four person team. During the study, we measured an array of salivary
biomarkers related to the various pathways of an individual's stress response for potential
elucidation of the major and minor physiological mediators driving adaptive stress
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responses while on a team. We hypothesized that individual salivary responses would
increase as part of a team, due to increased demands and forced social interaction to
complete a task. This work opens the door for a new avenue of mixtures research, where
interaction with other individuals in combination with emotional, physical, or chemical
exposure, can be considered as a component that may alter an individual’s response.

5.2 Materials and Methods
5.2.1 Subjects
The present study enrolled 17 subjects (18-22 y of age) from West Virginia
University’s Air Force Reserve Officers’ Training Corps (ROTC). Subjects were
introduced to the study during a university ROTC course, where the background
rationale, goals and risks were described in a power point presentation. Those in
attendance who were interested in participating were asked to provide their email address
to contact about availability for the study and to go over consent. A total of 17 subjects
were originally enrolled in the study (16 male, 1 female). After the individual phase of
the study, where subjects performed the tasks alone, one subject was dropped from the
study due to sampling errors. A total of 16 subjects (15 male, 1 female) were used for the
team portion of the study. Subjects were placed on teams using a random number
generator and their schedule availability. This study received approval from the
Institutional Review Board committee at West Virginia University and the United States
Army Medical Research and Materiel Command (USAMRMC) Office of Research
Protections.
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5.2.2 Salivary biomarkers
Saliva samples were collected immediately (less than 5 minutes) before the
mission clock started. Samples were collected with saliva collection aids purchased from
Salimetrics (State College, PA). All subjects had refrained from eating at least one hour
prior to sample collection. Unstimulated saliva samples were collected using the passive
drool method. Saliva samples were stored on ice (less than 3 h) before centrifugation (to
remove saliva debris) and long-term storage at -80°C. Salivary cytokines were assayed
using commercial kits. Salivary cytokines (GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL6, IL-8, IL-10 and TNF-α), were assayed using a commercial magnetic bead-based
suspension array 10-plex cytokine kit (cat. no. LHC0001M) purchased from Life
Technologies (Carlsbad, CA). Assay was performed in triplicate (25 µL/assay well)
according to manufacturer's protocol and measured with a Bio-plex 200 platform (BioRad, Hercules, CA). All samples (individual and team) analyzed with cytokine kits were
assayed over the course of a week.

5.3 Results and Discussion
The human body, especially endocrine, immune, and cardiovascular system, is
exceedingly sensitive and responsive to social interactions (Heaphy and Dutton, 2008).
These social interactions, whether they are with peers or those higher/lower in
employee/team status, can have a substantial impact on workplace efficiency,
performance, and, potentially, workplace-induced stress. As a key player in immune
surveillance and response, the mouth is in constant contact with airborne pollutants that
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are bacterial, viral, or chemical in nature (O'Connor et al., 2009). To gain a better
understanding of team dynamics and the impact of teamwork on an individual, we
compared initial salivary cytokine responses when subjects performed our mock hostage
rescue mission as an individual to initial salivary cytokine responses when they
performed it as part of a team. As an individual, subjects' initial summed salivary
cytokine responses (IL-1β, IL-10, IL-6, GM-CSF, IL-5, IFN-γ, TNF-α, IL-2, and IL-4)
were lower than when performing the mission as part of a four person team (Figures 5.12), with the exception of subject 4; thus agreeing with our hypothesis that the team
scenario would induce higher initial salivary cytokine levels than when they arrived to
perform the mission as an individual.

Figure 5.1 Initial salivary cytokine
responses as an individual. Salivary
samples were collected via passive drool
method less than 5 minutes before the first
mission started for the individual portion
of the study. Samples were assayed using
the
multiplex bead-based ELISA.
Horizontal line represents mean for the 4
individuals on their eventual team
(organized
by
team
to
easier
visualization). Error bars represent S.E.M.

Additionally, subjects' summed salivary cytokine levels were significantly
different when comparing individual and team responses (P < 0.01, paired student's ttest). However, in relation to performance, the time to complete the mock hostage rescue
mission as an individual (Table 5.1) was not significantly correlated to any single or
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Figure 5.2 Initial salivary cytokine
responses as a team. Salivary samples
were collected via passive drool
method less than 5 min before the first
mission of the team portion of the
study. Samples were assayed using the
multiplex
bead-based
ELISA.
Horizontal line represents mean for the
4 individuals on a team (during the
team portion of the study). Error bars
represent S.E.M.

summed salivary cytokine response (Table 5.2). This relation was also true for initial
salivary cytokine concentrations when performing the mission as part of a team.
The mechanism driving salivary cytokine responses after social interaction
exposure has yet to be elucidated. The whole-organism signaling response (intra- and
inter- cellular, as well as disparate organ system communication) involves a complex
spatiotemporal coordination of multiple components, whether they be proteins or
biomolecules, to integrate the stressful stimuli and produce a response. Neural-immune
(e.g, brain-cytokine) communication between the immune system and the central nervous
system (CNS) involves the coordination of many key players, such as the vagus,
glossopharyngeal, and trigeminal nerves, HPA axis, SNS, peripheral nervous system
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(PNS), and their corresponding downstream targets (tissues and organs) (Romeo et al.,
2001; Navarro et al., 2006; Thayer and Sternberg, 2010). The parasympathetic nervous
system (both afferent and efferent activity) in particular has been shown to be a major
player in neural-immune communication (Sternberg, 2006). It has been suggested that the
vagus nerve is highly innervated with IL-1 receptors (Goehler et al., 1997), and the
presence of afferent branches of vagus nerve (pharyngeal and laryngeal) in the mouth and
pharynx, as well as the overall gustatory system (Berthoud, 2008), may act as sensory
nerves for salivary IL-1β related to local immune responses or social and psychological
stressors. In addition to the vagus nerve, immune to brain communication may be relayed
by glossopharyngeal nerve afferents present in the posterior oral cavity (Watkins and
Maier, 2005; Goehler, 2008). In a study relating the glossopharyngeal nerve and immune
to brain communication, rats that underwent a bilateral glossopharyngeal nerve
transection were exposed to either lipopolysaccharide (LPS) or IL-1β via injection into
the soft palate (ISP) (Romeo et al., 2001). Sham rats exposed to LPS or IL-1β via ISP
showed a febrile dose-response. However, rats with bilateral glossopharyngeal nerve
transection had a reduced febrile response after LPS or IL-1β exposure, suggesting the
critical role of the glossopharyngeal nerve for immune to brain communication from the
oral cavity. The trigeminal nerve is also a key player in immune to brain communication.
The trigeminal nerve provides afferent somatosensory innervation to the face and oral
cavity in mammals (Byers and Dong, 1989). To investigate the relationship between
acute oral inflammation and brain communication, Navarro and colleagues (Navarro et
al., 2006) injected LPS into periodontal tissue and measured their febrile response. They
found that local periodontal inflammation induced a febrile response and maxillary
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trigeminal nerve transection attenuated this febrile response, suggesting the trigeminal
nerve is involved in oral inflammation to brain communication.

5.4 Conclusion
Military teams experience work environments that are both dynamic and
complex, under potentially life threatening circumstances, which indicates a high
workload (Cannon-Bowers et al., 1992; Urban et al., 1995). Even though these military
units undergo advanced physical and mental training in preparation for future missions,
performance may decline when it is most critical (i.e., during a mission) (Sandal et al., 1998).
Selection of a team that will withstand and adapt to any external stressors and work as a
cohesive unit toward mission success is imperative; both metrics and methods for selecting
these individuals are needed. In this study, we have shown that for a mock hostage rescue
mission in an urban setting, summed initial salivary cytokine responses increase when the
mission was performed with teammates as opposed to individually, suggesting a relationship
between potential social stress and salivary cytokines.
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